Pheochromocytoma

Pheochromocytoma
Other names	Phaeochromocytoma, adrenal medullary tumor, Chromaffin Cell Tumors, Paraganglioma
Normal remnant adrenal gland (left) with a pheochromocytoma (right) involving the adrenal medulla
Pronunciation	/ˌfiːoʊˌkroʊmoʊsʌɪˈtoʊmə/ [1] (fee-oh-kroh-moh-sahy-toh-muh)
Specialty	Endocrinology, oncology
Symptoms	Hypertension, tachycardia, sweating, headache, pallor
Complications	Hypertensive crisis
Causes	80% Genetic [2]
Diagnostic method	Elevated plasma free metanephrines, plasma catecholamines, urinary catecholamines, MRI, PET Scan
Treatment	Surgery, chemotherapy, radiation, and pharmacologic agents
Medication	Alpha blocker Doxazosin Prazosin Terazosin
Frequency	0.8 per 100,000 person-years [3]

Pheochromocytoma is a rare tumor of the adrenal medulla composed of chromaffin cells and is part of the paraganglioma (PGL) family of tumors, being defined as an intra-adrenal PGL . ^{[2] [4] [5]} These neuroendocrine tumors can be sympathetic, where they release catecholamines into the bloodstream which cause the most common symptoms, including hypertension (high blood pressure), tachycardia (fast heart rate), sweating, and headaches. ^{[6] [7]} Some PGLs may secrete little to no catecholamines, or only secrete paroxysmally (episodically), and other than secretions, PGLs can still become clinically relevant through other secretions or mass effect (most common with head and neck PGL). ^[8] PGLs of the head and neck are typically parasympathetic and their sympathetic counterparts are predominantly located in the abdomen and pelvis, particularly concentrated at the organ of Zuckerkandl at the bifurcation of the aorta. ^[9]

Etymology

1920s: from phaeochrome (another term for chromaffin), from Greek phaios 'dusky' + khrōma 'color', + -cyte.

Signs and symptoms

The symptoms of a sympathetic pheochromocytoma are related to sympathetic nervous system hyperactivity. ^[10] The classic triad includes headaches (likely related to elevated blood pressure, or hypertension), tachycardia/elevated heart rate, and diaphoresis (excessive sweating, particularly at night, also known as hyperhidrosis). ^[7] However, patients are unlikely to experience continuous symptoms. Due to the paroxysmal nature of catecholamine synthesis and release, patients may experience "attacks" or "spells" where they are suddenly overwhelmed with signs and symptoms of their tumor. ^[11] Attacks can occur spontaneously (without warning) or may be triggered by a variety of pharmaceutical agents (including histamine, metoclopramide, glucagon ^[12] and adrenocorticotropic hormone), foods that contain tyramine (cheese and wine), intraoperative tumor manipulation, intubation, or during anesthetic induction. ^[13]

Adrenal gland; the medulla (center, red) is the origin of the pheochromocytoma.

There is an adrenal gland, highlighted in yellow, on top of each of the kidneys.

Other clinical manifestations that have been reported include (in no particular order): ^{[6] [13]}

• Pallor
• Heat intolerance
• Weight loss
• Chest and/or abdominal discomfort
• Palpitations
• Nausea/vomiting
• Constipation
• Orthostatic hypotension — becoming light-headed or dizzy after swiftly changing positions
• Psychiatric manifestations
  • Anxiety, panic attacks, nervousness, tremors
• Hyperglycemia (high blood sugar)

Complications

While the symptoms of a pheochromocytoma are quite common, the disease has been referred to as "the great mimic". ^[14] It is estimated that approximately 0.1% of patients with hypertension have a pheochromocytoma, and it is often misdiagnosed as essential hypertension. ^[7] As symptoms are often paroxysmal (episodic/sporadic), patients may not immediately seek treatment as the problem "disappears on its own." Furthermore, when pictured in the ideal clinical scenario (an older woman in her mid-50s), the spontaneous attacks of flushing, sweating, and a racing heart may be mistaken for pre-menopausal related hot flashes. Unmanaged pheochromocytoma is dangerous and can lead to serious, potentially fatal, complications, including stroke and hypertension-induced organ damage. ^{[11] [15]} The cardiovascular system is the most commonly involved. ^{[16] [17] [18]}

In pregnancy, pheochromocytoma is associated with significant maternal and fetal mortality, mainly due to hypertensive crisis in the mother and intrauterine growth restriction in the fetus. ^{[19] [20]}

Misdiagnosis of pheochromocytoma can be deadly, as beta-blockers, often perscribed for hypertension, can lead to unopposed alpha in the context of pheochromocytoma. ^[21] Most mortality associated with diagnosed pheochromocytoma came from surgery and hypertensive crisis, but mortality has greatly improved. ^[22]

Cardiovascular system

1. Hypertensive crisis: Pheochromocytoma-related hypertensive emergencies are one of the most feared clinical manifestations. Attacks are random and may occur secondary to a trigger (see Signs and Symptoms above) or spontaneously after a catecholamine surge. ^[17] The prevailing symptom is elevated systolic blood pressure (> 200 mmHg) that is unresponsive to traditional treatment regimens and threatens end-organ damage. ^[16] Patients require immediate, life-saving treatment to prevent further damage to other organs and/or death.
2. Myocardial Ischemia/Infarction: A heart attack is often caused by a significant build-up of plaque (atherosclerosis) in the coronary vessels. Patients with pheochromocytoma present with myocardial infarctions despite an overall lack of plaque build-up, indicating a different mechanism for the myocardial infarction. Current research hypothesizes that the tumor secretes massive amounts of catecholamines, which directly interact with myocardial (heart) tissue and exert negative effects including oxygen deprivation, leading to accelerated scarring and cell death. ^[16]
3. Toxic Myocarditis: Even in patients without myocardial damage, excessive catecholamines can result in abnormal ST changes on an ECG. Norepinephrine (a catecholamine) is hypothesized to result in damaged cardiac tissue by inhibiting coronary blood flow and depriving cells of oxygen, thus resulting in ischemic tissue. ^[18] Fortunately, following tumor excision and the subsequent quelling of catecholamines, the damage has been proven reversible.
4. Cardiomyopathy: Pheochromocytomas have been implicated in various types of cardiomyopathy, including (myocarditis, see above), dilated cardiomyopathy, and stress-induced or Takotsubo cardiomyopathy. ^[23] As with the other cardiovascular-related complications, excess catecholamines are responsible for the increased myocardial burden and significant physiologic stress. ^{[24] [ non-primary source needed ]} Current literature indicates that most of the catecholamine-induced damage is reversible, thereby strengthening the argument for early and accurate diagnosis in order to allow for cardiac remodeling and prevent further destruction. ^{[23] [24]}
5. Arrhythmias: Sinus tachycardia is the most common abnormal heart rhythm associated with a pheochromocytoma and is experienced by patients as the feeling of a "fluttering heart" or palpitations. ^[16] Many other tachyarrhythmias (fast heart rate) have also been reported.

Nervous system

1. Cerebrovascular Accident (Stroke): Multiple reports have detailed transient ischemic attacks or strokes in patients with a pheochromocytoma. ^{[25] [ non-primary source needed ] [26] [27] [28] [29] [30] [31] [ non-primary source needed ]} In a study of 130 patients with pheochromocytoma, 7 patients were diagnosed with a transient ischemic attack (the neurologic deficit completely resolved) and 3 patients experienced a stroke with persistent symptoms. ^[32]
2. Headache: Headaches are one of the core clinical manifestations of a pheochromocytoma and can result in debilitating pain. ^[7] The majority of studied patients report their pain began and ended abruptly without warning and described the pain as a severe, bilateral throbbing (although the scale of severity was not published). While 71% of the studied patients reported headaches, just over 20% of the affected patients endorsed associated nausea, vomiting, photophobia, or phonophobia, which are typically associated with migraines. ^{[33] [ non-primary source needed ]}

Urinary system

1. Acute Renal Failure: Several reports have detailed rhabdomyolysis (rapid skeletal muscle breakdown) leading to acute kidney injury and the need for transient dialysis in the undiagnosed pheochromocytoma patient as their primary presenting symptom. ^{[34] [35] [36] [37] [ non-primary source needed ]} Kidney failure is brought about by catecholamine-induced muscle injury. Norepinephrine causes vessels to narrow, thereby limiting blood flow and inducing ischemia. ^[34]

Multiple organ dysfunction syndrome (MODS) ^[38] : Caused by an elevated inflammatory response, multiple organ dysfunction is a severe, life-threatening emergency with increasing mortality based on the number of systems involved. ^[39] Pheochromocytoma-related MODS is associated with multiple organ failure, hyperthermia > 40 degrees Celsius, neurologic manifestations, and cardiovascular instability resulting in either hypo or hypertension. ^[40] In contrast to a hypertensive crisis, pheochromocytoma-associated MODS may not respond to traditional alpha-receptor agents and may require emergent surgical excision if clinical stability is not achieved. ^[41]

Genetics

Current estimates predict that upwards of 40% of all pheochromocytomas are related to an inherited germline susceptibility mutation. ^[42] Of the remaining 60% of tumors, more than 30% are associated with a somatic mutation. ^[43] Given the high association with genetic inheritance, the United States Endocrine Society recommends that all patients diagnosed with a pheochromocytoma undergo an evaluation with a genetic counselor to consider genetic testing. ^[44] In the UK eligibility for NHS funded genetic testing is determined by criteria set by NHS England Genomics service. ^[45] The criteria in 2024 included all patients with paraganglioma and all patients with unilateral pheochromocytoma aged under 60. ^[46] The most recent data indicates that there are 25 pheochromocytoma susceptibility genes; however, just 12 are recognized as part of a well-known syndrome. ^[9] Determining the genetic status of a pheochromocytoma patient is crucial — each gene is inherited in a different pattern, associated with specific disease characteristics, and may respond more favorably to certain treatment options. Furthermore, early identification can guide physicians on screening recommendations for first degree relatives of patients with pheochromocytoma. ^[47] There is no current consensus for how and when asymptomatic carriers (individual who has a genetic variant associated with pheochromocytoma, but no current evidence of disease) should be evaluated. Conversations should occur at an individual level with the patient and their provider to develop a personalized screening plan that alternates between a biochemical (blood work) evaluation and whole-body imaging to monitor disease progression. ^{[48] [ non-primary source needed ]}

Pediatric considerations

Additional practices may help maintain the emotional and psychological well-being of the minor. Screening includes a multidisciplinary team (endocrinologist, oncologist, psychologist, geneticist, parent, and child) where the primary focus is supporting the child. ^[49]

• A positive result from testing during family-observed days of celebration may mask the happiness associated with these events in the future.
• Testing one pediatric sibling at a time allows the family to narrow their focus when results are returned and support each sibling individually.
• A negative result may be upsetting to a child if their sibling was positive; an opportunity to ask questions and process results may be helpful.

Hereditary syndromes

The following table(s) detail the clinical characteristics of the well-known hereditary pheochromocytoma gene variants ^{[50] [51] [52] [47] [43] [42] [53]}

Classic Pheochromocytoma Tumor Syndromes

	Gene	Inheritance	Penetrance	Metastatic Potential	1o Disease Characteristics
MEN2	RET	Autosomal Dominant	40–50%	<5%	Medullary thyroid carcinoma, hyperparathyroidism, marfanoid habitus, pheochromocytoma
VHL	VHL		10–30%	5%	Renal cell carcinoma, pancreatic NET, retinal and CNS hemangioblastoma, pheochromocytoma
NF1	NF1		1–5%	12%	Neurofibromas, cafe-au-lait macules, lisch nodules, pheochromocytoma

MEN2 (Multiple Endocrine Neoplasia-2); VHL (von-Hippel Lindau); NF1 (Neurofibromatosis-1); NET (Neuroendocrine Tumor); CNS (Central Nervous System)

Hereditary Paraganglioma Syndromes (SDHx)

	Gene	Inheritance	Penetrance	Metastatic Potential	1o Disease Characteristics
PGL1	SDHD	Autosomal Dominant Paternal Inheritance	90%	<5%	Head and neck paraganglioma, pheochromocytoma, gastrointestinal stromal tumor
PGL2	SDHAF2		100%	Low	Head and neck paraganglioma
PGL3	SDHC	Autosomal Dominant	Inconsistent	Inconsistent	Pheochromocytoma, head and neck paraganglioma, gastrointestinal stromal tumor
PGL4	SDHB		30–50%	30–70%	Head and neck paraganglioma, pheochromocytoma, gastrointestinal stromal tumor
PGL5	SDHA		10–15%	Low	Pheochromocytoma, head and neck paraganglioma, gastrointestinal stromal tumor

SDHx (Succinate Dehydrogenase Subunit x)

Other Pheochromocytoma Gene Mutations

	Inheritance	Penetrance	Metastatic Potential	1o Disease Characteristics
MAX	Autosomal Dominant	Inconsistent	<5%	Bilateral pheochromocytoma
TMEM127		Inconsistent	Low	Pheochromocytoma, head and neck paraganglioma

MAX (MYC Associated Factor X); TMEM127 (Transmembrane Protein 127)

Other gene variants

There have been several published case reports of other, rare pheochromocytoma-associated susceptibility genes:

1. Pacak–Zhuang Syndrome ^{[54] [55] [56] [57] [58]}
   • Hypoxia-inducible factor 2 alpha ( HIF2A)
   • Polycythemia
   • Duodenal somatostatinoma
   • Retinal and choroidal vascular changes
   • Paraganglioma/Pheochromocytoma
2. Pheochromocytoma and Giant Cell Tumor of Bone ^[59]
   • H3 histone, family 3A ( H3F3A), post-zygotic G34W
   • Pheochromocytoma/Paraganglioma
3. Carney Triad ^[60]
   • Gastrointestinal stromal tumor
   • Pulmonary chondroma
   • Paraganglioma
4. Carney-Stratakis Syndrome ^[61]
   • Gastrointestinal stromal tumor
   • Paraganglioma

Several additional gene variants have been described, but the provided information is inconsistent and a consensus has not been reached in the community if these mutations are truly pheochromocytoma susceptibility genes.^{[ citation needed ]}

Diagnosis

Differential

The typical primary symptom is hypertension, which may be either episodic or continual. A diagnosis of pheochromocytoma should be suspected when the patient simultaneously presents with hypertension and the classic triad of heart palpitations, headaches, and profuse sweating. ^[7]

If a patient has the characteristic signs and symptoms of a pheochromocytoma and the decision is made to pursue additional biochemical (blood work) evaluation, the differential diagnosis is important as it is more likely to be something other than a pheochromocytoma given the relative frequency of 0.8 per 100,000 person-years. ^[3]

All patients with phaeochromocytomas are currently considered to have a lifelong risk of metastases and therefore conceptually they are all considered 'malignant'. The risk of metastasis ranges from ~5 to 15%. There is no single histological finding or biomarker to reliably predict metastatic disease, and multiparameter scoring systems have been proposed ^[62]

Differential Diagnosis of Pheochromocytoma by System ^[a]

Endocrine	Cardiovascular	Neurologic	Psychiatric	Other
Hyperthyroidism	Heart Failure	Migraine	Anxiety	Porphyria
Carcinoid Syndrome	Arrhythmias	Stroke	Panic Disorder	Medications [b]
Hypoglycemia	Ischemic Heart Disease	Epilepsy	Substance Use [c]
Menopausal Syndrome	Baroreflex Failure	Meningioma	Factitious Disorder [d]
Medullary Thyroid Carcinoma	–	POTS	–

Notes

1. Adopted from Lenders et al., Phaeochromocytoma. The Lancet. 366(9486); 665–675. ^[4]
2. Monoamine Oxidase Inhibitors, Clonidine Withdrawal
3. Including but not limited to cocaine use
4. Misuse of over-the-counter medications such as pseudoephedrine hat are sympathomimetics

Biochemical evaluation

Gold standard

Elevated plasma free metanephrines is considered the gold standard diagnosis for pheochromocytoma. ^[63] Over 10 studies have confirmed that the sensitivity and specificity of this test is 97% and 93% respectively; however, there is still concern for false positive results in the correct clinical scenario. ^[6] When interpreting a biochemical analysis for pheochromocytoma, the provider must pay close attention to the (1) conditions of the collection, (2) all medications the patient is taking, and (3) their diet. ^[64]

1. Conditions of Collection: Unlike many routine laboratory tests that can be drawn at a moments notice, there are several recommendations that should be followed to ensure the ideal conditions and an accurate sample. Current research indicates that blood work should only be drawn after a patient has been resting supine (flat on their back) for 30 minutes before collection.^{[ non-primary source needed ] [65] [66]} Specific supine reference values should be used in this scenario. Ensuring these conditions is difficult and may be cost-prohibitive at most institutions. In these cases, a rested, supine draw can be repeated following a positive result in a seated position to eliminate false-positive results. ^[64]
2. Pharmaceutical Interference: Many prescription, over-the-counter, and illicit substances can interfere with the proper collection of plasma metanephrines and lead to false-positive results. Providers should review a patient's medication list in-detail and have a discussion if temporarily discontinuing any of the interfering medications is possible. The most reported medications to result in falsely elevated metanephrines include: β-adrenoceptor blockers, phenoxybenzamine, tricyclic antidepressants, monoamine oxidase inhibitors, serotonin norepinephrine reuptake inhibitors (SNRI), and methyldopa. ^{[67] [ non-primary source needed ] [64]} As the majority of these medications are commonly prescribed for psychiatric conditions, a conversation with the prescriber may be necessary to facilitate alternative therapeutic options while the patient is undergoing evaluation for a pheochromocytoma. ^[67] After any possible prescription medications have been held, it is important to review any over-the-counter medications/supplements as well as the commonly used acetaminophen and pseudoephedrine cause false elevations in metanephrine levels. ^{[64] [67]} Finally, it is important to have open, non-judgemental discussions about the patient's recreational substance use. Amphetamines, nicotine, and cocaine can result in marked plasma norepinephrine levels.
3. Lifestyle and Diet: As with most lab work, the patient should refrain from eating (fasting) after midnight the night prior to their collection. However, there are further recommendations specific to a metanephrines collection, including abstaining from nicotine, alcohol, and exercise for at least 12 hours prior to their lab draw. ^[9] Patients should also avoid catecholamine-containing foods (fruits, fruit drinks, chocolate, caffeine, tomatoes, beans, nuts, and potatoes) for a minimum of 24 hours prior to collection. ^{[7] [68] [69]}

While the above (3) conditions are likely to contribute to false-positive results if not controlled for, any value greater than 3 to 4 times the upper reference limit of normal should be considered diagnostic for a pheochromocytoma. ^{[44] [70]}

Alternative tests

Twenty-four hour urinary metanephrines are an acceptable alternative if the plasma test is unavailable. ^[71] Other additional biomarkers can be helpful to aid in the diagnosis of pheochromocytoma as well, most notable is Chromogranin A. In comparison to the specificity of elevated catecholamines in the pheochromocytoma patient, chromogranin A is a non-specific polypeptide that is high in a variety of neuroendocrine tumors. ^[72] However, a 2006 report from Italy found that over 90% of studied pheochromocytoma patients demonstrated elevated chromogranin A levels. ^[73] If metanephrine values are equivocal, chromogranin A can be used as an adjunct marker to predict the presence of a tumor.^{[ citation needed ]}

Borderline elevated metanephrines present a diagnostic challenge to the physician — the first step is to repeat the labs, taking extra precautions to follow the gold standard diagnosis described above, including the conditions of collection, pharmaceutical interference, and any potential diet and lifestyle habits that could alter the results. If the offending medications cannot be discontinued or repeated labs remained the same, consider administering a clonidine suppression test. ^{[7] [74]} In the 1970s, the drug clonidine hydrocloride swept the market as a novel agent for hypertension; however, the reported side-effects (nausea, vomiting, drowsiness, dryness of the eyes and mouth, constipation, and generalized weakness) limit compliance and have vastly diminished prescriptions. ^[75] While the adverse side-effects with clonidine are inconvenient, the most dangerous aspect of clonidine is withdrawal rebound hypertension — that is, when the medicine is abruptly discontinued, blood pressure may rapidly return or surpass the original value. ^{[76] [77] [78]} However, a one-time, weight-based dose can be utilized in limited settings to help determine disease status. ^[64] After fasting overnight, patient's will present to their testing site for a baseline metanephrines blood draw and clonidine administration. They will remain supine for (3) hours and a repeat blood draw will be taken. A positive result (indicating a pheochromocytoma) will occur if the plasma metanephrine levels remain elevated after clonidine is given. If the results are the same or fall, the test is negative and the patient does not have a pheochromocytoma. ^[64] It is important to note that if a patient does not have a pheochromocytoma, they may become extremely hypotensive following clonidine. Patients should not depend on themselves for transport following this test.

Plasma methoxytyramine is a breakdown product of the catecholamine, dopamine. Paragangliomas of the head and neck commonly secrete dopamine, but are referred to as "biochemically silent" because they do not cause the characteristic symptoms associated with a pheochromocytoma. However, methoxytyramine can be utilized to detect the tumors of the head and neck.^{[ non-primary source needed ] [79]} Further research indicates that the biomarker is also a useful indicator of metastatic disease — which is the only current biochemical evidence of metastases to date. ^[80]

Biochemical phenotypes

Structure of epinephrine

While diagnostic, laboratory values can also provide physician's with important information about the type, location, size, and associated tumor genotype. ^[70] There are (3) major, well-recognized biochemical phenotypes that can be used by health care providers to direct patient care. ^[81]

1. Adrenergic (Epinephrine and metanephrine)
   • More likely to indicate an adrenal tumor^{[ non-primary source needed ] [82]}
   • When plasma metanephrine levels were elevated to greater than 15% of the combined levels of normetanephrine and metanephrine, an adrenal tumor or a recurrence of an adrenal tumor that had already been excised can be predicted
   • Patients are more likely to present with the classic, paroxysmal (episodic) symptoms described above ^[70]

2. 

   Structure of norepinephrine

   Noradrengeric (Norepinephrine and normetanephrine)
   • More likely to indicate an extra-adrenal tumor ^[82]
   • Patients are more likely to present with continuous, persistent pheochromocytoma-related symptoms (hypertension and tachycardia) compared to those that are classically episode with an adrenergic phenotype ^[70]
   • Common in patients with von-Hippel Lindau and succinate dehydrogenase subunit X genetic variants ^[70]

3. 

   Structure of dopamine

   Dopaminergic (Dopamine and 3-methoxytyramine)
   • More likely to indicate an extra-adrenal tumor of the head and neck ^[81]
   • Patients are more likely to be asymptomatic; however, they may present with non-specific signs of nausea, vomiting, abdominal pain, diarrhea, and weight loss secondary to the stimulation of dopamine receptors throughout the gastrointestinal tract ^[70]
   • Particularly prevalent in patients with succinate dehydrogenase subunit B genetic variants ^[70]

Across both an adrenergic and a noradrenergic phenotype, the greater the sum of plasma or urinary concentrations of metanephrine and normetanephrine, the larger the expected tumor diameter. ^[82]

Tumor localization

Anatomic imaging

Anatomic imaging refers to computed tomography (CT) [CAT scan] or magnetic resonance imaging (MR) scans. These imaging modalities serve to initially locate the tumor and provide detailed information about size, morphology, and structural relation to adjacent internal structures. ^[83] Traditionally, a patient presents to their physician for symptoms concerning for a pheochromocytoma, which prompts a biochemical evaluation. If the results are positive, the patient is referred for anatomic imaging with a CT or MR scan. However, as anatomic imaging becomes more readily available, patients are referred to an endocrinologist after an incidental (unanticipated finding) adrenal nodule is found on a scan ordered for another reason. ^[63] For example, "Patient M" presents to his local emergency room for abdominal pain and a CT is ordered to rule-out appendicitis; however, the radiologist notes there is a 3.5 centimeter right adrenal mass.^{[ citation needed ]}

While there has not been a consensus on if CT or MR is the preferred imaging modality in pheochromocytoma, each method has its associated strengths and weaknesses. As CT expose the patient to ionizing radiation, MR is preferred in children and pregnant women. ^[84] Furthermore, the intravenous contrast used in CT can cause kidney damage and should therefore be avoided in patients with pre-existing damage. ^[85] However, patients who struggle with being in confined spaces for extended periods of time (claustrophobia) cannot often tolerate an MR as the machine is close-ended compared to the open-ended design of a CT. ^[86] When patients become anxious and begin to move in the machine, this causes motion artifact, which occurs less in CT-based images. ^[87]

Compared to CT and MR, ultrasound is not a preferred imaging modality and should be avoided in the pheochromocytoma patient. However, in specific patient populations where avoid ionizing radiation is the top priority (children, pregnant women), ultrasound can be used as an adjunct method when MR may be unavailable or the patient is unable to complete the scan. Furthermore, if an acute adrenal hemorrhage is suspected in a pheochromocytoma patient, ultrasound is a quick, painless, radiation-less, and cheap modality for a "first-pass" before the above imaging modalities or surgery is used to confirm the diagnosis. ^[88]

Functional imaging

The imaging modalities discussed below are for tumor characterization, confirmation of metastatic disease, and treatment planning — they are not used to discern tumor location or help the surgical team prepare for excision. ^[89] For most pheochromocytoma patients, functional imaging will follow a CT or MR. If anatomic imaging only demonstrates an adrenal tumor without evidence of disease anywhere else in the body and the metanephrine levels are overtly elevated, functional imaging can be foregone in favor of prompt surgical excision. ^[84] Over the last decade, there have been five functional techniques used to evaluate the pheochromocytoma patient (1) 18F-fluorodeoxyglucose positron emission tomography (¹⁸F-FDG PET), commonly referred to as the PET scan, (2) iodine-123 meta-iodobenzylguanadine (¹²³I-MIBG), (3) 18F-flurodihydroxyphenylalanine (¹⁸F-FDOPA),(4) 68Ga-DOTA coupled somatostatin analogs (⁶⁸Ga-DOTA),(5) 11C-Hydroxy ephedrine(HED-PET). From this point forward, these imaging modalities will be referred to in their abbreviated names found in parentheses.^{[ citation needed ]}

MIBG Scintigraphy — the pheochromocytoma is appreciated in the left panel on the right side of the screen (right panel; left side of the screen) as the darkened circle towards the abdomen. The darkened structure at the head of the patient is the thyroid gland, while the darkened structure in the pelvis of the patient is the bladder. This is normal physiologic uptake.

The first functional imaging technique utilized in pheochromocytoma patients was ¹²³I-MIBG scintigraphy. Given the compounds similar structure to the catecholamine norepinephrine (secreted by pheochromocytomas), MIBG was well-suited for uptake by most neuroendocrine tumors. ^[90] Furthermore, if a patient was found to be positive on an MIBG scan, they were eligible for MIBG treatment, offering additional avenues for those with widespread metastatic disease. ^[91] However, further investigation revealed that while MIBG excelled with adrenal lesions, it was far less superior in patients with extra-adrenal paragangliomas, particularly with specific genetic variants like those in the succinate dehydrogenase subunit–encoding genes (SDHx). ^[80] As the positron emission tomography scans were developed, MIBG has slowly lost its favor for the pheochromocytoma patient. ^[80]

FDG PET — the tumor is appreciated as the dark structure in the patient's left chest. Darkened structure at head of patient is the brain, posterior to the abdomen are the kidneys, in the pelvis is the bladder. These are normal.

Of the four above mentioned modalities, ¹⁸F-FDG PET is the most common and readily available functional imaging technique at most hospital systems, but the least-specific to neuroendocrine tumors (Image Left). In 2012, over 200 patients participated in a trial that compared the current gold standard of the time (MIBG/CT/MRI) to the novel FDG PET. Compared to its functional counterpart, FDG outperformed MIBG in detecting soft-tissue and bone metastases with higher specificity in patients with biochemically active tumors. ^[80]

Following the development of FDG-PET, neuroendocrine-specific PET scans began to emerge. One of the first favorable imaging modalities was ¹⁸F-FDOPA, which demonstrated a high sensitivity in detecting head and neck paragangliomas as well as non-metastatic disease outside of the head and neck. ^{[80] [92]} Unfortunately, in cases of metastatic disease, particularly related to succinate dehydrogenase subunit B ( SDHB) mutations, ¹⁸F-FDOPA fell inferior to the traditional FDG-PET. ^[93] However, for patients with genetic variants in other pheochromocytoma-susceptibility genes ( NF1, VHL, RET)¹⁸F-FDOPA has become the preferred radiopharmaceutical agent. ^[94]

The newest PET modality involves somatostatin receptor type two receptor imaging with ⁶⁸Ga-DOTA analogues. ^[87] Over the last decade, further research continues to indicate the superiority of this functional imaging modality in a wide range of clinical scenarios, even surpassing anatomic imaging (CT/MR) in pediatric patients with succinate dehydrogenase (SDHx) mutations.^{[ non-primary source needed ] [95]} While FDOPA inconsistently detected metastatic disease, ⁶⁸Ga-DOTA analogues have demonstrated superior localization of metastatic pheochromocytoma.^{[ non-primary source needed ] [96]} When directly compared in one head-to-head study in 2019, ⁶⁸Ga-DOTA analogues outperformed FDOPA, particularly in the detection of metastatic bone lesions. ^[97] An additional benefit of the DOTA analogues is the ability for treatment with peptide receptor radionuclide therapy, which will be discussed in the treatment section below. ^[98]

Also, HED-PET has shown to be an accurate tool to diagnose and rule out pheochromocytoma in complex clinical scenarios and to characterise equivocal adrenal tumours. ^[99]

Management

Surgery

Surgical resection is the only curative option for pheochromocytoma as of 2019. ^[100] A successful excision is a multidisciplinary effort involving the endocrinologist and the patient pre-operatively (discussed below) and the surgical team and anesthesiologist intraoperatively. Without frequent and adequate communication between all of the above-mentioned teams, a favorable outcome is much more difficult. ^[100] The United States Endocrine Society 2014 Clinical Practice Guideline for pheochromocytoma recommend a laparoscopic adrenalectomy (minimally invasive technique) for most adrenal tumors, unless they are invasive or are larger than 6.0 centimeters. ^[44] A 2018 systematic review suggests that laparoscopic retroperotenial adrenalectomy appears to reduce late morbidity, time to oral fluid or food intake and time to ambulation when compared to laparoscopic transperitoneal adrenalectomy, however there is uncertainty about these effects due to very low-quality evidence. ^[101] For outcomes such as all-cause mortality, early morbidity, socioeconomic effects, and operative and postoperative parameter, the evidence is uncertain about the effects of either interventions over the other. ^[101]

It is important to note that larger tumors even for those larger than 6.0 cm can be attempted with a minimally invasive approach, but the team should be prepared to convert to an open procedure if necessary.^{[ non-primary source needed ] [102] [103]} An open procedure (traditional surgical technique) is currently preferred for extra-adrenal disease, unless the tumor is small, non-invasive, and in an easy to maneuver location. While previous data indicated the need for a minimally invasive approach with malignant and/or metastatic disease, current research indicates a successful operation is feasible and results in a shorter hospital stay.^{[ non-primary source needed ] [104]} Literature within the last decade has also demonstrated that the robotic technique may be successfully utilized for adrenal tumors. ^[105]

Typically, complete or total adrenalectomy is performed; however, a technique referred to as "cortical-sparing" can leave a remnant (piece) of the adrenal gland in hopes of avoiding life-long steroid replacement if the left and right adrenal glands need to be removed. ^[106] The issue is particularly important in patients with MEN and VHL-related disease, which has a higher chance of bilateral pheochromocytomas.^{[ non-primary source needed ] [107]} The risk of leaving adrenal tissue is recurrent disease (tumor comes back). A 2019 cohort study reported that despite a 13% recurrent rate in patients who underwent a cortical-sparing adrenalectomy for pheochromocytoma, there was no decreased survival compared to their total adrenalectomy counterparts. ^[106]

Pre-operative management

Arguably, the most important part of a pheochromocytoma surgical plan is an adequate pre-operative blockade. Excess catecholamines have been described as a dormant volcano, ready to erupt at any time, wreaking catastrophic havoc on the body. ^[108] While an eruption can occur at any time, two of the most common triggers are anesthesia and direct tumor manipulation, making surgery one of the most dangerous times for a pheochromocytoma patient if not properly prepared.^{[ non-primary source needed ] [109]} In order to help circumvent a catecholamine-crisis, the United States Endocrine Society recommends that all patients with functional (hormonally active) tumors be started on a pre-operative alpha-adrenoceptor blockade a minimum of seven days prior to surgery. ^[44] There are several medication options depending on the clinical scenario, each with their own associated strengths and weaknesses.

Alpha blockade

If the patient's blood pressure is moderately elevated, a selective, short-acting alpha-1 adrenoceptor antagonist (doxazosin, prazosin, terazosin) is the preferred agent. ^[108] However, the patient should be warned about the potential side-effect known as "the first-dose phenomenon." When patients are initially exposed to one of the above agents, they may become lightheaded, dizzy, and nauseous, particularly when transferring from a seated to standing position due to a rapid decrease in blood pressure. ^[110] These effects will decrease with time, but providers can try to avoid them by starting at a low-dose and slowly increasing until they reach their desired amount. In patient's with uncontrolled hypertension, the non-selective alpha-1 and 2 adrenoceptor antagonist (phenoxybenzamine) should be utilized. ^[108] Unfortunately, compared to the selective agents listed above, phenoxybenzamine is much more expensive and may not be readily available to some patients. Common side effects include dry mouth, nasal congestion, and impaired male ejaculation, all of which do not cease with time and may limit patient compliance. ^[111] While uncommon, patients may have a hormonally-active pheochromocytoma and a normal blood pressure. One comparison from 2014 found that a small dose of a calcium-channel blocker (such as amlodipine) may be used pre-operatively in some people. ^[112] This will not drastically lower the patients blood pressure and make them hypotensive, but it will assist the surgical and anesthesia teams if there is hemodynamic instability during the operation.

Beta blockade

An elevated heart rate (tachycardia) and the feeling of a racing heart (palpitations) may follow after initiating an alpha-adrenoceptor antagonist. If that is the case, a beta-adrenoceptor antagonist is then prescribed to control the heart rate. ^[108] Just as with the alpha antagonists, there are selective (beta-1) and non-selective (beta-1 and beta-2) adrenoceptor antagonists. The selective agents (atenolol, metoprolol) are preferred to the non-selective agents (propranolol). ^[108] There are several (labetalol, carvedilol) combined alpha-beta-adrenoceptor antagonists. These agents should be avoided whenever possible as there is upwards of seven times more beta-adrenoceptor antagonism than alpha, which can worsen hypertension and lead to a catecholamine crisis.^{[ needs update ] [113]}

Complications

Beta-adrenoceptor antagonists should not be given alone in a pheochromocytoma patient — this can lead to severe consequences.^{[ non-primary source needed ] [114]} In 1995, a team of physicians from London described the death of a person who had been recently diagnosed pheochromocytoma after initiation of propranolol, a non-selective beta blocker. She quickly developed a hypertensive crisis leading to shock, myocardial infarction, heart failure, and dense right hemiplegia. Despite attempts at resuscitation, the person died several days later. ^[115] This complication is related to the impact that alpha and beta-adrenoceptor antagonists have on blood vessels combined with the actions of catecholamines. The normal blood vessel is open, allowing for adequate blood flow. When catecholamines activate the alpha receptor, the vessel constricts (gets smaller), which results in hypertension. ^[116] However, when catecholamines active the beta receptor, the blood vessel dilates (gets larger) and allows for increased blood flow, reducing the blood pressure. ^[117] If a pheochromocytoma patient is only started on a beta-adrenoceptor antagonist, this reverses the protective vasodilation and worsens the patient's hypertension.

Controversy

While the pre-operative alpha and beta blockade discussed above is overwhelmingly recognized as the standard of care, particularly in the United States, there has been discussion at the international level if alpha-blockade is necessary. In 2017, a team of researchers from Germany published an observational case series that called into question the current recommendations for alpha-blockade. ^[118] The study examined the intraoperative maximal systolic arterial pressure in people with and without alpha-adrenoceptor blockade and found no difference in complications between the two groups. ^[118] The following year, a group from France published a similar article with a warning against waiting an entire week to begin alpha-blockade. The French researchers called for immediate surgical intervention and consideration of steps to mitigate any intraoperative catecholamine crisis. ^[119] These articles resulted in rebuttals ^{[109] [120]} from research teams in the United States, but an international consensus has not yet been reached.

Perioperative fluid status

Excess catecholamines cause a decrease in the total blood volume, making a patient vulnerable to hypotension during the operation. ^[121] Therefore, a high-sodium diet with adequate fluid intake should be encouraged prior to surgery. ^[122] Some institutions in the United States will even admit patients the night prior to surgery for intravenous fluid replacement starting at midnight until the time of the operation. ^[108] However, a small trial from 2009 reported no difference in mortality in patients treated with preoperative intravenous fluids compared to those who did not. ^[123]

In a 2010 survey of 40 endocrinologists by researchers at the Cedars-Sinai Medical Center in Los Angeles, California, nearly all indicated the importance of preoperative volume resuscitation (having the patient take in plenty of fluids prior to surgery). However, after reviewing their patient data, over 60% of the same physicians failed to discuss salt-loading and adequate hydration.^{[ needs update ][ non-primary source needed ] [124]} When the patients were stratified by age, those that were younger received the advice to hydrate, but older patients did not. It was hypothesized that the providers chose to forego volume repletion in the older patient population for fear of their potential comorbidities (heart failure) where excess fluid is dangerous. ^[124] While there is still no recognized consensus or gold standard, providers should individualize the decision based on the patient's perceived nutritional standing, volume status, comorbidities, and ability to self-hydrate.

Post-operative management

Histopathology on the resected tumor confirms the diagnosis, by typical features as shown

The most common post-operative complications, likely causes, and treatment options are: ^{[125] [126]}

Cardiovascular

1. Hypertension: In the pheochromocytoma patient, postoperative hypertension could indicate incomplete tumor resection or another tumor of unknown location. However, the traditional, non-specific causes of postoperative hypertension including pain, fluid overload, and essential hypertension must also be considered. A perioperative hypertensive crisis is first treated with a 5.0 milligram (mg) intravenous bolus of phentolamine, with additional 5.0 mg dose every ten minutes until the blood pressure falls within an acceptable range.^{[ non-primary source needed ] [127]} If the blood pressure is only minimally elevated, the patient can resume their alpha and beta-adrenoceptor antagonist from prior to surgery. ^[125]
2. Hypotension: There are several reasons a patient may have low blood pressure in the post-operative period. First and foremost, the tumor (and its abundance of catecholamines causing high blood pressure) has been removed. Furthermore, the patient may still experience the effects of their alpha-adrenoceptor antagonist, which causes lower blood pressure. ^[126] First-line treatment for postoperative hypotension is aggressive fluid resuscitation, which is why ensuring the patient is well-hydrated (see above) prior to surgery is so imperative. ^[125] Vasopressors may be needed if the blood pressure does not respond to fluids.

Endocrine

1. Hyperglycemia: Catecholamines prevent the secretion of insulin — a hormone responsible for lowering the body's blood glucose (sugar). Blood glucose levels should be checked frequently in the perioperative period and insulin should be given as needed if levels are elevated. Following resection, tumor-related hyperglycemia is likely to resolve.
2. Hypoglycemia: After the tumor is removed, insulin is no longer inhibited, which can bring the blood glucose dangerously low. Symptoms include tremor, anxiety, palpitations, sweating, altered mental status (confusion), dizziness, and blurred vision. ^[128] A retrospective analysis of beta blocker found that some beta blocker use may cause people to more prone to hypoglycemia and not experience these symptoms, which could delay the diagnosis. ^[129]
3. Adrenal Insufficiency: Following a bilateral adrenalectomy (left and right), the patient is no longer capable of secreting the necessary hormones to keep their body functioning. Life-long steroid (hydrocortisone and fludrocortisone) oral supplementation may be required to ensure they do not develop adrenal insufficiency.^{[ non-primary source needed ] [130]} When the body is stressed (during surgery), the adrenal glands naturally produce more steroids; however, if the glands have been removed, they are unable to do so. Therefore, "stress-dosing" steroids are required and should be started intraopertively to mimic the natural physiology of the adrenal glands. ^[131] The typical regimen when post-operative adrenal insufficiency is thought to be likely: ^{[125] [126]}
   1. 50 milligram (mg) intravenous hydrocortisone in the operating room prior to anesthesia
   2. Repeat administration of 25–50 mg intravenous hydrocortisone every eight hours for a maximum of 72 hours (3 days) after the operation. Convert to oral replacement therapy as soon as the patient is able to take medication by mouth
   3. Patients should be transitioned to a normal maintenance (regular, daily) dose of steroids prior to discharge and referred to endocrinology for proper titration and management. Depending on the patient's total body surface area, the total typical daily dose of hydrocortisone is between 15 and 25 mg daily (divided into morning and afternoon pills). ^[132]
   4. Those who have lost both their adrenal glands will also require another steroid (mineralcorticoid replacement). The typical daily dose is between 50 and 200 micrograms of fludrocortisone ^[132]

There have been many other reported complications (renal failure, heart failure, intestinal pseudo-obstruction) following tumor resection. However, the above are more likely to be encountered, which is why their management has been specifically outlined here in this article.

Metastatic disease

Diagnosis and location

Metastatic pheochromocytoma is defined as the presence of tumor cells (chromaffin tissue) where they are not normally found. ^[133] Patients with a paraganglioma are more likely to develop metastases than those with a pheochromocytoma. ^[134] The most common extra-adrenal sites of metastases are the lymph nodes, lung, liver, and bone. ^[135] There have been several studied risk factors associated with the development of metastatic disease — while the patients genetic background plays an important role, the initial age of presentation and size of the tumor lead to negative outcomes. ^[133] Of all the genetic variants, succinate dehydrogenase subunit B (SDHB) mutations have the highest rates of developing metastatic disease. ^[134] Another study has reported increased mortality associated with male sex and synchronous metastases. ^[134] Metastases are divided into synchronous and metachronous; those that are synchronous have developed within several months of the primary tumor, while metachronous metastases do not appear for a significant period of time. ^[136]

Laparoscopic approach to the original disease, especially in big tumors, has been appointed as an important risk factor for tumoral seeding. ^[137]

Despite all of the below potential treatment options, recent literature highlights that (for most patients) metastatic pheochromocytoma is slow-growing. In patients with minimal disease burden, a "watch and wait" approach with frequent imaging to monitor disease is favorable, withholding treatment until evidence of progression is visualized. ^[138]

Treatment

Metastatic pheochromocytoma is best managed with a multidisciplinary team of oncologists, surgeons, radiologists, nuclear medicine physicians, and endocrinologists. There are several treatment options available to patients depending on the amount and location of disease:

Surgery — Normally, the goal of surgery is complete cytoreductive surgery; ^[137] leave no remnant of disease. ^[139] However, with widespread metastatic disease, this is not always feasible. Therefore, a surgical debulking procedure is performed (removing as much of the cancerous tissue as possible) in order to reduce patient symptoms by removing the source of catecholamines, improve response to chemo or radionuclide therapy, or simply decrease the size of the tumor. ^[140] Unfortunately, the intended relief from the procedure is often short-lived, especially if the patient has disease outside the abdomen. ^[140] A 2013 study from the National Institutes of Health reported that a majority of patients with recurrent biochemical evidence of disease within one year of the operation and less than 30% continued to be biochemically free of disease after five years. ^[140]

In contrast to an operation for non-metastatic disease, an open procedure may be preferred over a minimally invasive technique in order to circumvent potential tumor spread. ^[141] This also aids surgical visualization and offers the best opportunity to identify and remove metastatic lymph nodes. ^[142] Reports have also indicated the utility of administering a radionuclide agent like iodine-123 meta-iodobenzylguanadine (¹²³I-MIBG) prior to surgery and then scanning the patient intraoperatively with a probe to detect disease that may be missed with the naked eye. ^[143]

Patient receiving radiation therapy to the region of the head and neck. Full facial mold is in place to protect areas where they do not want exposure.

Radiation Therapy — With regard to pheochromocytoma, radiation techniques are primarily used for pain control, specifically with regards to bone metastases, local control of the disease, and to limit spinal cord compression. ^[144] A multidisciplinary team from the Mayo Clinic retrospectively reviewed all of their patients who underwent external beam radiation therapy from 1973 to 2015 and reported that 94% of patients acknowledged symptomatic improvement and over 80% of patients showed no evidence of recurrent disease five years post-therapy. ^[145] Another report from the same institution looked at almost two decades of patients who underwent radiofrequency ablation, cryoablation, or percutaneous ethanol injection for metastatic pheochromocytoma and reported that local control was achieved in over 85% of targeted lesions and that 92% of procedures were associated with reduced pain and/or symptoms of catecholamine excess. ^[146]

Chemotherapy — The most common chemotherapy regimen for metastatic pheochromocytoma is cyclophosphamide, vincristine, and dacarbazine, collectively known as CVD. ^{[147] [148]} Response to therapy is measured by a reduction in total tumor volume as well as symptomatic relief, reported by the patient. A systematic review and meta-analysis of unstratified pheochromocytoma patients who underwent CVD therapy showed that 37% of patients had a significant reduction in tumor volume, while 40% of patients experienced lower catecholamine burden. ^[147] While there was no difference in overall survival between patients whose tumors shrunk versus those without a response (no reduction in tumor burden via imaging), even in non-responders, patients reported feeling better, blood pressure was lower, and some patients were even able to undergo surgery following disease stabilization with CVD. ^[149] When patients are studied by various categories, research has suggested that females are less likely to have extended survival with CVD chemotherapy compared to their male counterparts. ^[150] Genetic status has been shown to greatly impact response to CVD. A team of researchers from the National Institutes of Health reported that patient's with succinate dehydrogenase subunit B (SDHB) mutations are not only more likely to initially respond to CVD, but that they also experienced over 30 months of progression-free survival (time until tumor returned) with continued administration. ^[151]

However, CVD is not the only proven chemotherapeutic regimen in the pheochromocytoma patient. A 2018 report demonstrated the remarkable response of two SDHB patients who failed CVD chemotherapy (disease progressed despite medication), but were then treated with temozolomide (TMZ) and had progression free survival of 13 and 27 months, indicating that TMZ can be considered as an alternative treatment regimen in those who have progressed on CVD. ^[152] Several studies have since reported successful responses with TMZ, particularly in the SDHB sub-population. ^{[153] [154]}

Radionuclide Therapy

• Iodine-131 meta-iodobenzylguanadine (MIBG)
  • As was mentioned in the functional imaging section above, MIBG is not only useful in locating the presence of metastatic disease, but also as an available treatment modality. In 2019, a multi-center phase 2 trial looked at the safety and efficacy of MIBG therapy in metastatic or unresectable (not conducive to surgery) pheochromocytoma patients and the results were promising. ^[155] Median overall survival was 36.7 months and 92% of patients had at least a partial positive response (tumor shrinkage) or stable disease without progression within the first year of the study. Furthermore, over a fourth of the patients were able to decrease their anti-hypertensive medications and reported symptomatic improvement. ^[155] There are several patients who are not eligible for MIBG treatment, including pregnant women (exposure to radiation is harmful to the fetus), women who are actively breast feeding, patients in renal failure, and those are who not expected to live longer than three months. ^[156] As MIBG therapy can destroy the thyroid, protective medications (potassium iodide) are started prior to treatment and need to be continued for at least three weeks after therapy concludes. ^[156] Associated side effects (muscle weakness, nausea, vomiting and hematologic (blood) toxicities, are common, but often minimal, and can be mitigated with slow, steady dosing. ^[157]

Top: Purple lesions are metastatic disease detected with DOTATATE imaging. Bottom: Same patient. Purple lesions are metastatic disease detected with FDG PET

• Peptide Receptor Radionuclide Therapy (PRRT)
  • The newest of the treatment options, PRRT utilizes the 68-Ga DOTA analogues mentioned above in the functional imaging section. ^[158] Treatment with ¹⁷⁷Lu-DOTATATE first demonstrated success in patients with undifferentiated neuroendocrine tumors and then trials began with metastatic pheochromocytoma patients. ^{[159] [160]} In 2019, Vyakaranam et al. published favourable results for their 22 patients who underwent PRRT, with partial response in 2 patients and stable disease (no progression) in the remaining 20 patients. ^[161] Overall toxicity was low, with no high-grade haematological (blood) or kidney damage reported. ^[161] At the end of that same year, a systemic review looked at all published articles (12) where metastatic pheochromocytoma patients underwent PRRT and found that treatment-related adverse events are minimal, with only 5 out of 102 patients choosing to voluntarily initiate treatment discontinuation. ^[162] Newer reports have detailed the utility of combining ⁹⁰Y-DOTATATE with the traditionally studied ¹⁷⁷Lu analog and the various possibilities and novel treatment options these combinations will bring to the field. ^[98] While the overall reported side-effects have been promising, it is important to note that a collaborative effort between the National Institutes of Health and Radboud University Medical Centre reported two unfortunate cases of rapid disease progression following a remarkable, almost complete response to PRRT. While the etiology of their recurrence is unknown, the team speculated that an elevated tumor marker (Ki-67) could be an indication of a poor response to PRRT and called for pre-PRRT assessments to include Ki-67 values to help individualize patient treatment plans. ^[163]

Prognosis

According to the National Cancer Institute, prognosis is defined as the likely outcome of a disease OR, the chance of recovery or a recurrence. ^[164] This is an extremely difficult question when it comes to pheochromocytoma, and the answer depends on the patients genetic status, presence of metastatic disease, and the location of their primary tumor. ^[165] An article about prognosis published in 2000 reported a 91% 5-year survival rate in their patient population; however, over 86% of their patients had sporadic tumors (no known genetic mutation), which commonly have low malignant potential. ^[166] In 2019, a consortium of almost twenty European medical centers looked at the prognosis of malignant pheochromocytoma and the data starkly varies from the report of sporadic, single tumors, with a median survival of 6.7 years. ^[167] Overall survival improved if the patient had (1) disease of the head and neck compared to abdomen, (2) less than 40 years of age, (3) and if their biochemistry was less than five times the upper reference limit of normal. ^[167]

Recent literature has detailed several factors that predict accelerated progression of disease and higher mortality rates, including patients who choose to forego surgical resection of their primary tumor, larger tumors at initial presentation, older age at initial diagnosis, and a shortened time from primary tumor to presence of metastases. ^[168] The actual location of the metastases can also indicate prognosis, with osseous lesions (bone) faring better than their soft-tissue (lung, liver) counterparts. ^[169]

Epidemiology

According to the North American Neuroendocrine Tumor Society, the prevalence of pheochromocytoma is between 1:2,500 and 1:6,500, meaning that for every 2,500–6,500 people, there is (on average) one person with pheochromocytoma. ^[170] In the United States, this equates to an annual incidence (new cases per year) of 500 to 1,600 cases. ^[170] However, approximations in the early 2000s reported that upwards of 50% of pheochromocytoma diagnoses are at autopsy; therefore, the above estimations may be lower than expected. ^[13] In a 50-year autopsy case series, the Mayo Clinic reviewed 54 pheochromocytoma cases between 1928–1977 and discovered that just 24% of the patients were correctly diagnosed prior to their death.^{[ needs update ][ non-primary source needed ] [171]} Outside of the United States, several countries have documented their own epidemiological studies and compared them to what is known in North America. In the first national, epidemiological population-based study in Asia utilizing Korean National Health Insurance Service data, the prevalence of a pheochromocytoma was reported at 2.13 per 100,000 persons with an incidence of 0.18 per 100,000 person-years. ^[172] This is lower than the occurrence reported from Rochester, Minnesota (0.8 per 100,000 person-years), in a study conducted from 1950 to 1979. ^[3] However, the Netherlands also conducted a study using a nationwide registry and reported incidence results of 0.57 per 100,000 person-years from 2011 to 2015, which was a significant increase from their 0.37 cases per 100,000 person-years reported from 1995 to 1999. ^[173] Current hypotheses for why the incidence of pheochromocytoma is growing in the Dutch population point to the advent of modern imaging evaluation and the ability to detect these tumors prior to death. ^[174] While each of the above studies reported varying incidence and prevalence values, all have indicated that the average age at initial diagnosis is between the third to fifth decade of life. ^[175] When younger patients are diagnosed with a pheochromocytoma, there should be a high suspicion for hereditary disease, as genetic anticipation (earlier disease onset with each generation) is associated with some mutations. ^[176]

Likelihood of diagnosis when an adrenal-nodule is identified; pheochromocytoma is in yellow near the top-right corner.

Classically, the pheochromocytoma "rules of 10" have been taught, particularly to medical students: ^[177]

• 10% of patients have malignant disease
• 10% of patients have bilateral (both left and right adrenal glands) disease
• 10% of patients have extra-adrenal (paraganglioma) disease
• 10% of patients have inherited (familial disease)

Despite the prominence in many respected textbooks, these guidelines have since been established as inaccurate and are not used in current epidemiological discussions. ^[175]

As suggested above, incidental imaging has become a major player in the diagnosis of patients with pheochromocytoma, with current estimates that 10–49% of all cases diagnosed after imaging was obtained for another reason. When an adrenal nodule (potential tumor) is discovered on computed tomography or magnetic resonance imaging, there is a 5–10% chance the lesion is a pheochromocytoma. ^[175] The incidence of adrenal tumors is found in the infographic above, with pheochromocytoma noted in yellow in the top right corner.

History

Professor Ludwig Pick, the German physician who first coined the term "pheochromocytoma" in 1912 after recognizing the color-change associated with the addition of chromium salts

In 1800, an Irish physician (Charles Sugrue) penned a case report to the London Medical and Physical Journal describing the peculiar case of an 8-year-old male patient who had had seemingly random fits of pain concentrated in the abdomen accompanied by "a hectic flush distinctly marked on each cheek" with a "constant profuse and universal perspiration." ^[178] Following his death, a group of physicians performed an autopsy to determine cause of death and discovered a six-inch oblong tumor composed of an unknown "yellow-ish coloured substance" coming from the capsula renalis (what is now known as the adrenal gland). ^[178] This would become the first known clinical description of a pheochromocytoma, but as no features of the tumor itself were described, complete credit is given to the German Felix Fraenkel, who provided a clinical and morphologic picture of this tumor. ^{[179] [180]} While various physicians were recognizing symptoms and treating patients, Czech biologist Alfred Kohn reported his discovery of the paraganglia system, which would later become crucial to the diagnosis of these tumors. Furthermore, he also introduced the term "chromaffin," allowing pathologists to recognize tumors that arose from the adrenal gland. ^[181]

In 1908, two pathologists, Henri Alezais and Felix Peyron, introduced the scientific community to "paraganglioma" after they discovered extra-adrenal tissue that reacted to chromium salts, which mimicked the reaction of the adrenal medulla. ^[182] Just four years later, German pathologist Ludwig Pick coined the term "pheochromocytoma" after he observed the consistent color change in tumors associated with the adrenal medulla. ^[183] Many surgeons attempted to remove these tumors over the next decade, but their patients died intraoperatively from shock. In 1926, Charles Mayo (a founder of the Mayo Clinic) became the first physician to successfully excise a pheochromocytoma. ^[183] However, Mayo was likely unaware of the diagnosis prior to the operation. Not until 1929 was a pheochromocytoma recognized preoperatively. ^[13] Throughout the early 1900s, the operative mortality rate for a pheochromocytoma ranged from 30 to 45%. Retrospective series have postulated that these alarmingly high death rates were due to the lack of a pre-operative blockade with alpha and beta-adrenoceptor antagonist and the need for modern anesthesia practices. ^[184] From this point forward, physician-scientists have been recognizing patterns in patients with pheochromocytoma and identifying genetic associations and various syndromes. ^[13]

Society and culture

While a rare disease, there have been several references to pheochromocytoma in popular culture and the media, specifically medical television dramas. Additionally, there is a strong online patient advocacy community that works to connect patients with rare diseases and allows them to meet other individuals who are experiencing similar diagnoses and treatment strategies.

Zebra culture

The zebra has become a powerful symbol in the pheochromocytoma advocacy community and represents the rare medical cases that are more likely to be misdiagnosed.

In the medical community, students are often taught "when you hear hoofbeats, think horses, not zebras." ^[185] In other words, common diagnoses are common, so healthcare professionals should first rule out what is most expected (the horses) before diving into the rare etiologies that are far less likely to be correct (the zebras). However, the symbol of the zebra has become increasingly powerful to the rare disease community and resulted in several organizations, societies, and special events (Rare Disease Day) to draw attention to the least common option sometimes being the correct diagnosis. ^[186]

The National Organization for Rare Disorders is a United States–based advocacy parent organization with the goal of promoting awareness and research opportunities to cure rare diseases. ^[187] Groups such as these encourage patients to become their own advocates and change agents in their healthcare decision-making processes.

Media

In July 2012, an actual pheochromocytoma patient, Tannis Brown, former vice-president of the PheoPara Troopers, was featured on the Discovery Fit & Health Network program Diagnosis: Dead or Alive. ^[188] The show highlighted her personal struggle with misdiagnosed disease as many physicians felt her episodic headaches and hypertension (high blood pressure) were related to stress. ^[189]

In the seventh and eighth seasons of Grey's Anatomy, series regular Henry has a Von Hippel-Lindau (VHL) mutation that has resulted in a pheochromocytoma. The story arc was met with mixed opinions from the rare disease community. ^[190] The executive director of the VHL Alliance was happy with the portrayal of a VHL patient in mainstream media, but pointed out that of the four scripts she knew of with a VHL patient, three involved a pheochromocytoma, which occurs in less than a fifth of all VHL patients. ^{[191] [192]}

A case of pheochromocytoma was featured in the first episode of season 2 of House, M.D. . Dr. House and his team are tasked with diagnosing and treating an inmate on death row. Although the patient has a violent history of homicide, Dr. House suspects that his episodic rage and aggression may be caused by an adrenaline secreting tumor. Dr. House is able to locate the tumor and diagnoses the patient with pheochromocytoma. Dr. Foreman, one of the doctors, attempts to appeal the inmate's death penalty on the basis that he was unable to control his actions due to his tumor. This kind of legal defense is rarely successful, however.

References

1. "PHAEOCHROMOCYTOMA | Meaning & Definition for UK English". Lexico.com. Archived from the original on February 25, 2021. Retrieved 2022-08-24.
2. Gimenez-Roqueplo AP, Robledo M, Dahia PL (April 2023). "Update on the genetics of paragangliomas". Endocr Relat Cancer. 30 (4): e220373. doi:10.1530/ERC-22-0373. PMC   10029328 . PMID   36748842.
3. Beard CM, Sheps SG, Kurland LT, Carney JA, Lie JT (December 1983). "Occurrence of pheochromocytoma in Rochester, Minnesota, 1950 through 1979". Mayo Clinic Proceedings. 58 (12): 802–4. PMID   6645626.
4. Lenders JW, Eisenhofer G, Mannelli M, Pacak K (20–26 August 2005). "Phaeochromocytoma". Lancet. 366 (9486): 665–75. doi:10.1016/S0140-6736(05)67139-5. PMID   16112304. S2CID   208788653.
5. Oyasu R, Yang XJ, Yoshida O, eds. (2008). "What is the difference between pheochromocytoma and paraganglioma? What are the familial syndromes that have pheochromocytoma as a component? What are the pathologic features of pheochromocytoma indicating malignancy?". Questions in Daily Urologic Practice: Updates for Urologists and Diagnostic Pathologists. Tokyo: Springer Japan. pp. 280–4. doi:10.1007/978-4-431-72819-1_49. ISBN   978-4-431-72819-1.
6. Lenders JW, Pacak K, Walther MM, Linehan WM, Mannelli M, Friberg P, et al. (March 2002). "Biochemical diagnosis of pheochromocytoma: which test is best?". JAMA. 287 (11): 1427–34. doi: 10.1001/jama.287.11.1427 . PMID   11903030.
7. "Internal Medicine". JAMA. 286 (8): 971. 2001-08-22. doi:10.1001/jama.286.8.971-jbk0822-2-1. ISSN   0098-7484.
8. Williams MD (September 2017). "Paragangliomas of the Head and Neck: An Overview from Diagnosis to Genetics". Head Neck Pathol. 11 (3): 278–287. doi:10.1007/s12105-017-0803-4. PMC   5550402 . PMID   28321772.
9. Kellerman RD, Rakel D (2020). Conn's Current Therapy. Elsevier–Health Science. ISBN   978-0-323-79006-2. OCLC   1145315791.
10. Tevosian SG, Ghayee HK (December 2019). "Pheochromocytomas and Paragangliomas". Endocrinology and Metabolism Clinics of North America. 48 (4): 727–750. doi:10.1016/j.ecl.2019.08.006. PMID   31655773. S2CID   204947638.
11. Zuber SM, Kantorovich V, Pacak K (June 2011). "Hypertension in pheochromocytoma: characteristics and treatment". Endocrinology and Metabolism Clinics of North America. 40 (2): 295–311, vii. doi:10.1016/j.ecl.2011.02.002. PMC   3094542 . PMID   21565668.
12. Hosseinnezhad A, Black RM, Aeddula NR, Adhikari D, Trivedi N (2011). "Glucagon-induced pheochromocytoma crisis". Endocrine Practice. 17 (3): e51-4. doi:10.4158/EP10388.CR. PMID   21324811.
13. Manger WM (August 2006). "An overview of pheochromocytoma: history, current concepts, vagaries, and diagnostic challenges". Annals of the New York Academy of Sciences. 1073 (1): 1–20. Bibcode:2006NYASA1073....1M. doi:10.1196/annals.1353.001. PMID   17102067. S2CID   21423113.
14. ^{[ non-primary source needed ]}Mitchell L, Bellis F (September 2007). "Phaeochromocytoma--"the great mimic": an unusual presentation". Emergency Medicine Journal. 24 (9): 672–3. doi:10.1136/emj.2007.049569. PMC   2464664 . PMID   17711956.
15. Riester A, Weismann D, Quinkler M, Lichtenauer UD, Sommerey S, Halbritter R, et al. (December 2015). "Life-threatening events in patients with pheochromocytoma". European Journal of Endocrinology. 173 (6): 757–64. doi: 10.1530/EJE-15-0483 . PMID   26346138.
16. Prejbisz A, Lenders JW, Eisenhofer G, Januszewicz A (November 2011). "Cardiovascular manifestations of phaeochromocytoma". Journal of Hypertension. 29 (11): 2049–60. doi:10.1097/HJH.0b013e32834a4ce9. PMID   21826022. S2CID   23444609.
17. Young WF (December 2007). "Adrenal causes of hypertension: pheochromocytoma and primary aldosteronism". Reviews in Endocrine & Metabolic Disorders. 8 (4): 309–20. doi:10.1007/s11154-007-9055-z. PMID   17914676. S2CID   6009557.
18. Liao WB, Liu CF, Chiang CW, Kung CT, Lee CW (September 2000). "Cardiovascular manifestations of pheochromocytoma". The American Journal of Emergency Medicine. 18 (5): 622–5. doi:10.1053/ajem.2000.7341. PMID   10999582.
19. Lenders JW (February 2012). "Pheochromocytoma and pregnancy: a deceptive connection". European Journal of Endocrinology. 166 (2): 143–50. doi: 10.1530/EJE-11-0528 . PMID   21890650.
20. Kattah AG, Garovic VD (May 2013). "The management of hypertension in pregnancy". Advances in Chronic Kidney Disease. 20 (3): 229–39. doi:10.1053/j.ackd.2013.01.014. PMC   3925675 . PMID   23928387.
21. Blake, Michael A. "Pheochromocytoma Medication".
22. Prejbisz A, Lenders JW, Eisenhofer G, Januszewicz A (February 2013). "Mortality associated with phaeochromocytoma". Horm Metab Res. 45 (2): 154–8. doi:10.1055/s-0032-1331217. PMID   23322516.
23. Zhang R, Gupta D, Albert SG (December 2017). "Pheochromocytoma as a reversible cause of cardiomyopathy: Analysis and review of the literature". International Journal of Cardiology. 249: 319–323. doi:10.1016/j.ijcard.2017.07.014. PMID   29121733.
24. Agrawal S, Shirani J, Garg L, Singh A, Longo S, Longo A, et al. (March 2017). "Pheochromocytoma and stress cardiomyopathy: Insight into pathogenesis". World Journal of Cardiology. 9 (3): 255–260. doi: 10.4330/wjc.v9.i3.255 . PMC   5368675 . PMID   28400922.
25. Van YH, Wang HS, Lai CH, Lin JN, Lo FS (November 2002). "Pheochromocytoma presenting as stroke in two Taiwanese children". Journal of Pediatric Endocrinology & Metabolism. 15 (9): 1563–7. doi:10.1515/jpem.2002.15.9.1563. PMID   12503867. S2CID   37955071.
26. Abourazzak S, Atmani S, Arqam LE, Chaouki S, Labib S, Harrandou M, et al. (May 2010). "Cerebral ischaemic stroke and bilateral pheochromocytoma". BMJ Case Reports. 2010: bcr1220092535. doi:10.1136/bcr.12.2009.2535. PMC   3047554 . PMID   22736758.
27. Dagartzikas MI, Sprague K, Carter G, Tobias JD (February 2002). "Cerebrovascular event, dilated cardiomyopathy, and pheochromocytoma". Pediatric Emergency Care. 18 (1): 33–5. doi: 10.1097/00006565-200202000-00011 . PMID   11862137. S2CID   44533238.
28. Cohen JK, Cisco RM, Scholten A, Mitmaker E, Duh QY (April 2014). "Pheochromocytoma crisis resulting in acute heart failure and cardioembolic stroke in a 37-year-old man". Surgery. 155 (4): 726–7. doi:10.1016/j.surg.2012.11.013. PMID   23305592.
29. Lin PC, Hsu JT, Chung CM, Chang ST (2007). "Pheochromocytoma Underlying Hypertension, Stroke, and Dilated Cardiomyopathy". Texas Heart Institute Journal. 34 (2): 244–6. OCLC   679006463. PMC   1894695 . PMID   17622380.
30. Buchbinder NA, Yu R, Rosenbloom BE, Sherman CT, Silberman AW (December 2009). "Left ventricular thrombus and embolic stroke caused by a functional paraganglioma". Journal of Clinical Hypertension. 11 (12): 734–7. doi: 10.1111/j.1751-7176.2009.00182.x . PMC   8673247 . PMID   20021531. S2CID   30275458.
31. Luiz HV, da Silva TN, Pereira BD, Santos JG, Gonçalves D, Manita I, Portugal J (December 2013). "Malignant paraganglioma presenting with hemorrhagic stroke in a child". Pediatrics. 132 (6): e1709-14. doi:10.1542/peds.2013-0492. PMID   24276837. S2CID   7618637.
32. Potapova G, Chazova I, Kuznetsov N, Sitina V, Popov E, Gavrilov I (June 2011). "Pheochromocytoma and Stroke". Journal of Hypertension. 29: e505. doi:10.1097/00004872-201106001-01534.
33. Anderson NE, Chung K, Willoughby E, Croxson MS (April 2013). "Neurological manifestations of phaeochromocytomas and secretory paragangliomas: a reappraisal". Journal of Neurology, Neurosurgery, and Psychiatry. 84 (4): 452–7. doi:10.1136/jnnp-2012-303028. PMID   23204473. S2CID   207005321.
34. Shemin D, Cohn PS, Zipin SB (November 1990). "Pheochromocytoma presenting as rhabdomyolysis and acute myoglobinuric renal failure". Archives of Internal Medicine. 150 (11): 2384–5. doi:10.1001/archinte.1990.00390220118024. PMID   2241450.
35. Hamada N, Akamatsu A, Joh T (January 1993). "A case of pheochromocytoma complicated with acute renal failure and cardiomyopathy". Japanese Circulation Journal. 57 (1): 84–90. doi: 10.1253/jcj.57.84 . PMID   8437346.
36. Celik H, Celik O, Guldiken S, Inal V, Puyan FO, Tugrul A (February 2014). "Pheochromocytoma presenting with rhabdomyolysis and acute renal failure: a case report". Renal Failure. 36 (1): 104–7. doi:10.3109/0886022X.2013.832856. PMID   24059440. S2CID   2062065.
37. Takabatake T, Kawabata M, Ohta H, Yamamoto Y, Ishida Y, Hara H, Hattori N (July 1985). "Acute renal failure and transient, massive proteinuria in a case of pheochromocytoma". Clinical Nephrology. 24 (1): 47–9. PMID   4017298.
38. Lorz W, Cottier C, Imhof E, Gyr N (1993). "Multiple organ failure and coma as initial presentation of pheochromocytoma in a patient with multiple endocrine neoplasia (MEN) type II A". Intensive Care Medicine. 19 (4): 235–8. doi:10.1007/BF01694777. PMC   7095150 . PMID   8103532.
39. Marshall JC (2001). "The multiple organ dysfunction syndrome". In Holzheimer RG, Mannick JA (eds.). Surgical Treatment: Evidence-Based and Problem-Oriented. Munich: Zuckschwerdt. ISBN   978-3-88603-714-8.
40. Newell KA, Prinz RA, Pickleman J, Braithwaite S, Brooks M, Karson TH, Glisson S (August 1988). "Pheochromocytoma multisystem crisis. A surgical emergency". Archives of Surgery. 123 (8): 956–9. doi:10.1001/archsurg.1988.01400320042007. PMID   2899426.
41. Whitelaw BC, Prague JK, Mustafa OG, Schulte KM, Hopkins PA, Gilbert JA, McGregor AM, Aylwin SJ (January 2014). "Phaeochromocytoma [corrected] crisis". Clin Endocrinol (Oxf). 80 (1): 13–22. doi:10.1111/cen.12324. PMID   24102156.
42. Fishbein L (February 2016). "Pheochromocytoma and Paraganglioma: Genetics, Diagnosis, and Treatment". Hematology/Oncology Clinics of North America. 30 (1): 135–50. doi:10.1016/j.hoc.2015.09.006. PMID   26614373.
43. Mercado-Asis LB, Wolf KI, Jochmanova I, Taïeb D (January 2018). "Pheochromocytoma: A Genetic and Diagnostic Update" (PDF). Endocrine Practice. 24 (1): 78–90. doi:10.4158/EP-2017-0057. PMID   29144820. S2CID   45860930.
44. Lenders JW, Duh QY, Eisenhofer G, Gimenez-Roqueplo AP, Grebe SK, Murad MH, et al. (June 2014). "Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline". The Journal of Clinical Endocrinology and Metabolism. 99 (6): 1915–42. doi: 10.1210/jc.2014-1498 . PMID   24893135.
45. "National genomic test directory". NHS England. 2018–2024.
46. "R223 Inherited phaeochromocytoma and paraganglioma excluding NF1" (PDF). National genomic test directory: Testing criteria for rare and inherited disease. NHS England. July 2024. p. 81. Version 7.
47. Kavinga Gunawardane PT, Grossman A (October 2017). "The clinical genetics of phaeochromocytoma and paraganglioma". Archives of Endocrinology and Metabolism. 61 (5): 490–500. doi: 10.1590/2359-3997000000299 . PMC   10522248 . PMID   29166454.
48. Jochmanova I, Wolf KI, King KS, Nambuba J, Wesley R, Martucci V, et al. (August 2017). "SDHB-related pheochromocytoma and paraganglioma penetrance and genotype–phenotype correlations". Journal of Cancer Research and Clinical Oncology. 143 (8): 1421–35. doi:10.1007/s00432-017-2397-3. PMC   5505780 . PMID   28374168.
49. ^{[ non-primary source needed ]}Lahlou-Laforêt K, Consoli SM, Jeunemaitre X, Gimenez-Roqueplo AP (May 2012). "Presymptomatic genetic testing in minors at risk of paraganglioma and pheochromocytoma: our experience of oncogenetic multidisciplinary consultation". Hormone and Metabolic Research. 44 (5): 354–8. doi:10.1055/s-0032-1311568. PMID   22517555. S2CID   28354220.
50. Neumann HP, Young WF, Krauss T, Bayley JP, Schiavi F, Opocher G, et al. (August 2018). "65 YEARS OF THE DOUBLE HELIX: Genetics informs precision practice in the diagnosis and management of pheochromocytoma". Endocrine-Related Cancer. 25 (8): T201–T219. doi: 10.1530/ERC-18-0085 . hdl: 11577/3302932 . PMID   29794110.
51. Favier J, Amar L, Gimenez-Roqueplo AP (February 2015). "Paraganglioma and phaeochromocytoma: from genetics to personalized medicine". Nature Reviews. Endocrinology. 11 (2): 101–11. doi:10.1038/nrendo.2014.188. PMID   25385035. S2CID   26205361.
52. Dahia PL (February 2014). "Pheochromocytoma and paraganglioma pathogenesis: learning from genetic heterogeneity". Nature Reviews. Cancer. 14 (2): 108–19. doi: 10.1038/nrc3648 . PMID   24442145. S2CID   31457232.
53. Jochmanova I, Pacak K (January 2018). "Genomic Landscape of Pheochromocytoma and Paraganglioma". Trends in Cancer. 4 (1): 6–9. doi:10.1016/j.trecan.2017.11.001. PMC   5819363 . PMID   29413423.
54. ^{[ non-primary source needed ]}Taïeb D, Yang C, Delenne B, Zhuang Z, Barlier A, Sebag F, Pacak K (May 2013). "First report of bilateral pheochromocytoma in the clinical spectrum of HIF2A-related polycythemia-paraganglioma syndrome". The Journal of Clinical Endocrinology and Metabolism. 98 (5): E908-13. doi:10.1210/jc.2013-1217. PMC   3644612 . PMID   23539726.
55. ^{[ non-primary source needed ]}Yang C, Sun MG, Matro J, Huynh TT, Rahimpour S, Prchal JT, et al. (March 2013). "Novel HIF2A mutations disrupt oxygen sensing, leading to polycythemia, paragangliomas, and somatostatinomas". Blood. 121 (13): 2563–6. doi:10.1182/blood-2012-10-460972. PMC   3612863 . PMID   23361906.
56. ^{[ non-primary source needed ]}Pacak K, Jochmanova I, Prodanov T, Yang C, Merino MJ, Fojo T, et al. (May 2013). "New syndrome of paraganglioma and somatostatinoma associated with polycythemia". Journal of Clinical Oncology. 31 (13): 1690–8. doi:10.1200/JCO.2012.47.1912. PMC   3807138 . PMID   23509317.
57. ^{[ non-primary source needed ]}Zhuang Z, Yang C, Lorenzo F, Merino M, Fojo T, Kebebew E, et al. (September 2012). "Somatic HIF2A gain-of-function mutations in paraganglioma with polycythemia". The New England Journal of Medicine. 367 (10): 922–30. doi:10.1056/NEJMoa1205119. PMC   3432945 . PMID   22931260.
58. ^{[ non-primary source needed ]}Dmitriev PM, Wang H, Rosenblum JS, Prodanov T, Cui J, Pappo AS, et al. (December 2019). "Vascular Changes in the Retina and Choroid of Patients With EPAS1 Gain-of-Function Mutation Syndrome". JAMA Ophthalmology. 138 (2): 148–155. doi:10.1001/jamaophthalmol.2019.5244. PMC   7042897 . PMID   31876943.
59. ^{[ non-primary source needed ]}Toledo RA, Qin Y, Cheng ZM, Gao Q, Iwata S, Silva GM, et al. (May 2016). "Recurrent Mutations of Chromatin-Remodeling Genes and Kinase Receptors in Pheochromocytomas and Paragangliomas". Clinical Cancer Research. 22 (9): 2301–10. doi:10.1158/1078-0432.CCR-15-1841. PMC   4854762 . PMID   26700204.
60. Carney JA (2013). "Carney triad". Frontiers of Hormone Research. 41: 92–110. doi:10.1159/000345672. ISBN   978-3-318-02330-5. PMID   23652673.
61. Stratakis CA, Carney JA (July 2009). "The triad of paragangliomas, gastric stromal tumours and pulmonary chondromas (Carney triad), and the dyad of paragangliomas and gastric stromal sarcomas (Carney-Stratakis syndrome): molecular genetics and clinical implications". Journal of Internal Medicine. 266 (1): 43–52. doi:10.1111/j.1365-2796.2009.02110.x. PMC   3129547 . PMID   19522824.
62. "BlueBooksOnline".
63. Neumann HP, Young WF, Eng C (August 2019). "Pheochromocytoma and Paraganglioma". The New England Journal of Medicine. 381 (6): 552–565. doi:10.1056/NEJMra1806651. PMID   31390501. S2CID   199505276.
64. Eisenhofer G, Goldstein DS, Walther MM, Friberg P, Lenders JW, Keiser HR, Pacak K (June 2003). "Biochemical diagnosis of pheochromocytoma: how to distinguish true- from false-positive test results". The Journal of Clinical Endocrinology and Metabolism. 88 (6): 2656–66. doi: 10.1210/jc.2002-030005 . PMID   12788870.
65. Griffin TP, Casey R, Wall D, Bell M, O'Shea PM (August 2016). "Evaluating the optimum rest period prior to blood collection for fractionated plasma free metanephrines analysis". Practical Laboratory Medicine. 5: 39–46. doi:10.1016/j.plabm.2016.05.001. PMC   5574516 . PMID   28856203.
66. Lenders JW, Willemsen JJ, Eisenhofer G, Ross HA, Pacak K, Timmers HJ, Sweep CG (February 2007). "Is supine rest necessary before blood sampling for plasma metanephrines?". Clinical Chemistry. 53 (2): 352–4. doi: 10.1373/clinchem.2006.076489 . PMID   17200132.
67. Neary NM, King KS, Pacak K (June 2011). "Drugs and pheochromocytoma—don't be fooled by every elevated metanephrine". The New England Journal of Medicine. 364 (23): 2268–70. doi:10.1056/NEJMc1101502. PMC   4724800 . PMID   21651412.
68. de Jong WH, Post WJ, Kerstens MN, de Vries EG, Kema IP (June 2010). "Elevated urinary free and deconjugated catecholamines after consumption of a catecholamine-rich diet". The Journal of Clinical Endocrinology and Metabolism. 95 (6): 2851–5. doi: 10.1210/jc.2009-2589 . PMID   20382681.
69. de Jong WH, Eisenhofer G, Post WJ, Muskiet FA, de Vries EG, Kema IP (August 2009). "Dietary influences on plasma and urinary metanephrines: implications for diagnosis of catecholamine-producing tumors". The Journal of Clinical Endocrinology and Metabolism. 94 (8): 2841–9. doi: 10.1210/jc.2009-0303 . PMID   19567530.
70. Alrezk R, Suarez A, Tena I, Pacak K (2018-11-27). "Update of Pheochromocytoma Syndromes: Genetics, Biochemical Evaluation, and Imaging". Frontiers in Endocrinology. 9: 515. doi: 10.3389/fendo.2018.00515 . PMC   6277481 . PMID   30538672.
71. Martucci VL, Pacak K (January 2014). "Pheochromocytoma and paraganglioma: diagnosis, genetics, management, and treatment". Current Problems in Cancer. 38 (1): 7–41. doi:10.1016/j.currproblcancer.2014.01.001. PMC   3992879 . PMID   24636754.
72. d'Herbomez M, Do Cao C, Vezzosi D, Borzon-Chasot F, Baudin E (September 2010). "Chromogranin A assay in clinical practice". Annales d'Endocrinologie. 71 (4): 274–80. doi:10.1016/j.ando.2010.04.004. PMID   20538257.
73. Grossrubatscher E, Dalino P, Vignati F, Gambacorta M, Pugliese R, Boniardi M, et al. (September 2006). "The role of chromogranin A in the management of patients with phaeochromocytoma". Clinical Endocrinology. 65 (3): 287–93. doi:10.1111/j.1365-2265.2006.02591.x. PMID   16918946. S2CID   19506144.
74. Därr R, Lenders JW, Stange K, Kindel B, Hofbauer LC, Bornstein SR, Eisenhofer G (January 2013). "[Diagnosis of pheochromocytoma and paraganglioma: the clonidine suppression test in patients with borderline elevations of plasma free normetanephrine]". Deutsche Medizinische Wochenschrift. 138 (3): 76–81. doi:10.1055/s-0032-1327395. PMID   23299341. S2CID   206339408.
75. Kosman ME (July 1975). "Evaluation of clonidine hydrochloride (Catapres). A new antihypertensive agent". JAMA. 233 (2): 174–6. doi:10.1001/jama.1975.03260020060030. PMID   1173448.
76. England JF (May 1977). "Clonidine rebound hypertension". The Medical Journal of Australia. 1 (20): 756–7. doi:10.5694/j.1326-5377.1977.tb131095.x. PMID   875850. S2CID   67982391.
77. Geyskes GG, Boer P, Dorhout Mees EJ (January 1979). "Clonidine withdrawal. Mechanism and frequency of rebound hypertension". British Journal of Clinical Pharmacology. 7 (1): 55–62. doi:10.1111/j.1365-2125.1979.tb00897.x. PMC   1429594 . PMID   760743.
78. Malaty J, Malaty IA (October 2014). "Hypertensive urgency: an important aetiology of rebound hypertension". BMJ Case Reports. 2014: bcr2014206022. doi:10.1136/bcr-2014-206022. PMC   4208112 . PMID   25336552.
79. Rao D, Peitzsch M, Prejbisz A, Hanus K, Fassnacht M, Beuschlein F, et al. (August 2017). "Plasma methoxytyramine: clinical utility with metanephrines for diagnosis of pheochromocytoma and paraganglioma". European Journal of Endocrinology. 177 (2): 103–113. doi:10.1530/EJE-17-0077. PMC   5488393 . PMID   28476870.
80. Lenders JW, Eisenhofer G (June 2017). "Update on Modern Management of Pheochromocytoma and Paraganglioma". Endocrinology and Metabolism. 32 (2): 152–161. doi:10.3803/EnM.2017.32.2.152. PMC   5503859 . PMID   28685506.
81. Gupta G, Pacak K (June 2017). "Precision Medicine: An Update on Genotype/Biochemical Phenotype Relationships in Pheochromocytoma/Paraganglioma Patients". Endocrine Practice. 23 (6): 690–704. doi:10.4158/EP161718.RA. PMC   7470624 . PMID   28332883.
82. Eisenhofer G, Lenders JW, Goldstein DS, Mannelli M, Csako G, Walther MM, et al. (April 2005). "Pheochromocytoma catecholamine phenotypes and prediction of tumor size and location by use of plasma free metanephrines". Clinical Chemistry. 51 (4): 735–44. doi: 10.1373/clinchem.2004.045484 . PMID   15718487.
83. Histed SN, Lindenberg ML, Mena E, Turkbey B, Choyke PL, Kurdziel KA (April 2012). "Review of functional/anatomical imaging in oncology". Nuclear Medicine Communications. 33 (4): 349–61. doi:10.1097/MNM.0b013e32834ec8a5. PMC   3295905 . PMID   22314804.
84. Timmers HJ, Taieb D, Pacak K (May 2012). "Current and future anatomical and functional imaging approaches to pheochromocytoma and paraganglioma". Hormone and Metabolic Research. 44 (5): 367–72. doi:10.1055/s-0031-1299712. PMC   4714588 . PMID   22399235.
85. McCullough PA, Choi JP, Feghali GA, Schussler JM, Stoler RM, Vallabahn RC, Mehta A (September 2016). "Contrast-Induced Acute Kidney Injury". Journal of the American College of Cardiology. 68 (13): 1465–73. doi: 10.1016/j.jacc.2016.05.099 . PMID   27659469.
86. Caraiani C, Dong Y, Rudd AG, Dietrich CF (December 2018). "Reasons for inadequate or incomplete imaging techniques". Medical Ultrasonography. 20 (4): 498–507. doi: 10.11152/mu-1736 . PMID   30534659.
87. Castinetti F, Kroiss A, Kumar R, Pacak K, Taieb D (August 2015). "15 YEARS OF PARAGANGLIOMA: Imaging and imaging-based treatment of pheochromocytoma and paraganglioma". Endocrine-Related Cancer. 22 (4): T135-45. doi: 10.1530/ERC-15-0175 . PMID   26045470.
88. Leung K, Stamm M, Raja A, Low G (February 2013). "Pheochromocytoma: the range of appearances on ultrasound, CT, MRI, and functional imaging". AJR. American Journal of Roentgenology. 200 (2): 370–8. doi:10.2214/AJR.12.9126. PMID   23345359.
89. Chaudhary V, Bano S (September 2012). "Anatomical and functional imaging in endocrine hypertension". Indian Journal of Endocrinology and Metabolism. 16 (5): 713–21. doi: 10.4103/2230-8210.100659 . PMC   3475894 . PMID   23087854.
90. Rufini V, Treglia G, Perotti G, Giordano A (January 2013). "The evolution in the use of MIBG scintigraphy in pheochromocytomas and paragangliomas". Hormones. 12 (1): 58–68. doi:10.1007/bf03401287. PMID   23624132. S2CID   4716903.
91. van Hulsteijn LT, Niemeijer ND, Dekkers OM, Corssmit EP (April 2014). "(131)I-MIBG therapy for malignant paraganglioma and phaeochromocytoma: systematic review and meta-analysis". Clinical Endocrinology. 80 (4): 487–501. doi: 10.1111/cen.12341 . PMID   24118038. S2CID   38456445.
92. Santhanam P, Taïeb D (December 2014). "Role of (18) F-FDOPA PET/CT imaging in endocrinology". Clinical Endocrinology. 81 (6): 789–98. doi: 10.1111/cen.12566 . PMID   25056984. S2CID   204992362.
93. Taïeb D, Tessonnier L, Sebag F, Niccoli-Sire P, Morange I, Colavolpe C, et al. (2008). "The role of 18F-FDOPA and 18F-FDG-PET in the management of malignant and multifocal phaeochromocytomas". Clinical Endocrinology. 69 (4): 580–6. doi:10.1111/j.1365-2265.2008.03257.x. OCLC   798350389. PMID   18394015. S2CID   205284382.
94. Taïeb D, Hicks RJ, Hindié E, Guillet BA, Avram A, Ghedini P, et al. (September 2019). "European Association of Nuclear Medicine Practice Guideline/Society of Nuclear Medicine and Molecular Imaging Procedure Standard 2019 for radionuclide imaging of phaeochromocytoma and paraganglioma". European Journal of Nuclear Medicine and Molecular Imaging. 46 (10): 2112–37. doi:10.1007/s00259-019-04398-1. PMC   7446938 . PMID   31254038. S2CID   195738862.
95. Jha A, Ling A, Millo C, Gupta G, Viana B, Lin FI, et al. (May 2018). "18F-FDG and anatomic imaging in the detection of succinate dehydrogenase mutation (SDHx)–related pheochromocytoma and paraganglioma in the pediatric population". European Journal of Nuclear Medicine and Molecular Imaging. 45 (5): 787–797. doi:10.1007/s00259-017-3896-9. PMC   6707509 . PMID   29204718.
96. Janssen I, Chen CC, Millo CM, Ling A, Taieb D, Lin FI, et al. (September 2016). "PET/CT comparing (68)Ga-DOTATATE and other radiopharmaceuticals and in comparison with CT/MRI for the localization of sporadic metastatic pheochromocytoma and paraganglioma". European Journal of Nuclear Medicine and Molecular Imaging. 43 (10): 1784–91. doi:10.1007/s00259-016-3357-x. PMC   8194362 . PMID   26996779. S2CID   23005709.
97. Kroiss AS, Uprimny C, Shulkin BL, Gruber L, Frech A, Jazbec T, et al. (March 2019). "18F-DOPA PET/CT". Revista Espanola de Medicina Nuclear e Imagen Molecular. 38 (2): 94–99. doi:10.1016/j.remn.2018.09.004. PMID   30630744. S2CID   196533632.
98. Mak IY, Hayes AR, Khoo B, Grossman A (2019). "Peptide Receptor Radionuclide Therapy as a Novel Treatment for Metastatic and Invasive Phaeochromocytoma and Paraganglioma". Neuroendocrinology. 109 (4): 287–298. doi: 10.1159/000499497 . PMID   30856620. S2CID   75140335.
99. Vyakaranam AR, Crona J, Norlén O, Hellman P, Sundin A (June 2019). "¹¹C-hydroxy-ephedrine-PET/CT in the Diagnosis of Pheochromocytoma and Paraganglioma". Cancers. 11 (6): 847. doi: 10.3390/cancers11060847 . PMC   6627429 . PMID   31248124.
100. Wiseman D, Lakis ME, Nilubol N (July 2019). "Precision Surgery for Pheochromocytomas and Paragangliomas". Hormone and Metabolic Research. 51 (7): 470–482. doi:10.1055/a-0926-3618. PMC   8572371 . PMID   31307109.
101. Arezzo A, Bullano A, Cochetti G, Cirocchi R, Randolph J, Mearini E, et al. (Cochrane Metabolic and Endocrine Disorders Group) (December 2018). "Transperitoneal versus retroperitoneal laparoscopic adrenalectomy for adrenal tumours in adults". The Cochrane Database of Systematic Reviews. 2018 (12): CD011668. doi:10.1002/14651858.CD011668.pub2. PMC   6517116 . PMID   30595004.
102. Aggeli C, Nixon AM, Parianos C, Vletsis G, Papanastasiou L, Markou A, et al. (October 2017). "Surgery for pheochromocytoma: A 20-year experience of a single institution". Hormones. 16 (4): 388–395. doi: 10.14310/horm.2002.1759 . PMID   29518759. S2CID   4730354.
103. Zhang, Liang; Chen, Danlei; Pang, Yingxian; Guan, Xiao; Xu, Xiaowen; Wang, Cikui; Xiao, Qiao; Liu, Longfei (July 2022). "Surgical treatment of large pheochromocytoma (>6 cm): A 10-year single-center experience". Asian Journal of Urology. 9 (3): 294–300. doi:10.1016/j.ajur.2022.04.004. PMC   9399532 . PMID   36035344.
104. Goffredo P, Adam MA, Thomas SM, Scheri RP, Sosa JA, Roman SA (August 2015). "Patterns of Use and Short-Term Outcomes of Minimally Invasive Surgery for Malignant Pheochromocytoma: A Population-Level Study". World Journal of Surgery. 39 (8): 1966–73. doi:10.1007/s00268-015-3040-6. PMID   25821949. S2CID   9017845.
105. Berber E, Mitchell J, Milas M, Siperstein A (August 2010). "Robotic posterior retroperitoneal adrenalectomy: operative technique". Archives of Surgery. 145 (8): 781–4. doi:10.1001/archsurg.2010.148. PMID   20713932.
106. Neumann HP, Tsoy U, Bancos I, Amodru V, Walz MK, Tirosh A, et al. (August 2019). "Comparison of Pheochromocytoma-Specific Morbidity and Mortality Among Adults With Bilateral Pheochromocytomas Undergoing Total Adrenalectomy vs Cortical-Sparing Adrenalectomy". JAMA Network Open. 2 (8): e198898. doi:10.1001/jamanetworkopen.2019.8898. PMC   6692838 . PMID   31397861.
107. Lee JE, Curley SA, Gagel RF, Evans DB, Hickey RC (December 1996). "Cortical-sparing adrenalectomy for patients with bilateral pheochromocytoma". Surgery. 120 (6): 1064–70, discussion 1070–1. doi:10.1016/S0039-6060(96)80056-0. PMID   8957496.
108. Pacak K (November 2007). "Preoperative management of the pheochromocytoma patient". The Journal of Clinical Endocrinology and Metabolism. 92 (11): 4069–79. doi: 10.1210/jc.2007-1720 . PMID   17989126.
109. Wolf KI, Santos JR, Pacak K (January 2019). "Why Take the Risk? We Only Live Once: The Dangers Associated with Neglecting a Pre-Operative Alpha Adrenoceptor Blockade in Pheochromocytoma Patients". Endocrine Practice. 25 (1): 106–8. doi:10.4158/EP-2018-0455. PMC   6478021 . PMID   30289301.
110. Graham RM, Thornell IR, Gain JM, Bagnoli C, Oates HF, Stokes GS (November 1976). "Prazosin: the first-dose phenomenon". British Medical Journal. 2 (6047): 1293–4. doi:10.1136/bmj.2.6047.1293. PMC   1689975 . PMID   793676.
111. Kleeman FJ (June 1977). "Phenoxybenzamine". The Journal of Urology. 117 (6): 814. doi:10.1016/s0022-5347(17)58643-7. PMID   875171.
112. Brunaud L, Boutami M, Nguyen-Thi PL, Finnerty B, Germain A, Weryha G, et al. (December 2014). "Both preoperative alpha and calcium channel blockade impact intraoperative hemodynamic stability similarly in the management of pheochromocytoma". Surgery. 156 (6): 1410–7, discussion1417-8. doi:10.1016/j.surg.2014.08.022. PMID   25456922.
113. Clark BK (May 1992). "Beta-adrenergic blocking agents: their current status". AACN Clinical Issues in Critical Care Nursing. 3 (2): 447–60. doi:10.4037/15597768-1992-2016. PMID   1349490.
114. Luiz HV, Tanchee MJ, Pavlatou MG, Yu R, Nambuba J, Wolf K, et al. (July 2016). "Are patients with hormonally functional phaeochromocytoma and paraganglioma initially receiving a proper adrenoceptor blockade? A retrospective cohort study". Clinical Endocrinology. 85 (1): 62–9. doi:10.1111/cen.13066. PMC   4899243 . PMID   26998836.
115. Sheaves R, Chew SL, Grossman AB (January 1995). "The dangers of unopposed beta-adrenergic blockade in phaeochromocytoma". Postgraduate Medical Journal. 71 (831): 58–9. doi:10.1136/pgmj.71.831.58-a. PMC   2397901 . PMID   7708599.
116. van Brummelen P, Jie K, van Zwieten PA (1986). "Alpha-adrenergic receptors in human blood vessels". British Journal of Clinical Pharmacology. 21 (Suppl 1): 33S–39S. doi:10.1111/j.1365-2125.1986.tb02851.x. PMC   1400759 . PMID   2871855.
117. Chruscinski A, Brede ME, Meinel L, Lohse MJ, Kobilka BK, Hein L (November 2001). "Differential distribution of beta-adrenergic receptor subtypes in blood vessels of knockout mice lacking beta(1)- or beta(2)-adrenergic receptors". Molecular Pharmacology. 60 (5): 955–62. doi:10.1124/mol.60.5.955. PMID   11641423.
118. Groeben H, Nottebaum BJ, Alesina PF, Traut A, Neumann HP, Walz MK (February 2017). "Perioperative α-receptor blockade in phaeochromocytoma surgery: an observational case series". British Journal of Anaesthesia. 118 (2): 182–9. doi: 10.1093/bja/aew392 . PMID   28100521. S2CID   5979863.
119. Lentschener C, Baillard C, Dousset B, Gaujoux S (February 2019). "Dogma is Made to be Broken. Why Are We Postponing Curative Surgery to Administer Ineffective Alpha Adrenoreceptor Blockade in Most Patients Undergoing Pheochromocytoma Removal?". Endocrine Practice. 25 (2): 199. doi:10.4158/1934-2403-25.2.199. PMID   30817194. S2CID   73480157.
120. Santos JR, Wolf KI, Pacak K (February 2019). "A Necessity, Not a Second Thought: Pre-Operative Alpha-Adrenoceptor Blockade in Pheochromocytoma Patients". Endocrine Practice. 25 (2): 200–1. doi:10.4158/1934-2403-25.2.200. PMC   7451406 . PMID   30817195.
121. Challis BG, Casey RT, Simpson HL, Gurnell M (February 2017). "Is there an optimal preoperative management strategy for phaeochromocytoma/paraganglioma?". Clinical Endocrinology. 86 (2): 163–7. doi:10.1111/cen.13252. PMID   27696513. S2CID   1473367.
122. Jiang M, Ding H, Liang Y, Tang J, Lin Y, Xiang K, et al. (March 2018). "Preoperative risk factors for haemodynamic instability during pheochromocytoma surgery in Chinese patients". Clinical Endocrinology. 88 (3): 498–505. doi:10.1111/cen.13544. PMID   29292527. S2CID   46820948.
123. Lentschener C, Gaujoux S, Thillois JM, Duboc D, Bertherat J, Ozier Y, Dousset B (April 2009). "Increased arterial pressure is not predictive of haemodynamic instability in patients undergoing adrenalectomy for phaeochromocytoma". Acta Anaesthesiologica Scandinavica. 53 (4): 522–7. doi:10.1111/j.1399-6576.2008.01894.x. PMID   19239408. S2CID   25480499.
124. ^{[ non-primary source needed ]}Wong C, Yu R (July 2010). "Preoperative preparation for pheochromocytoma resection: physician survey and clinical practice". Experimental and Clinical Endocrinology & Diabetes. 118 (7): 400–4. doi:10.1055/s-0029-1225339. PMID   19609840. S2CID   260136542.
125. Mamilla D, Araque KA, Brofferio A, Gonzales MK, Sullivan JN, Nilubol N, Pacak K (July 2019). "Postoperative Management in Patients with Pheochromocytoma and Paraganglioma". Cancers. 11 (7): 936. doi: 10.3390/cancers11070936 . PMC   6678461 . PMID   31277296.
126. Naranjo J, Dodd S, Martin YN (August 2017). "Perioperative Management of Pheochromocytoma". Journal of Cardiothoracic and Vascular Anesthesia. 31 (4): 1427–39. doi:10.1053/j.jvca.2017.02.023. PMID   28392094.
127. Aronow WS (May 2017). "Treatment of hypertensive emergencies". Annals of Translational Medicine. 5 (Suppl 1): S5. doi: 10.21037/atm.2017.03.34 . PMC   5440310 . PMID   28567387.
128. Iqbal A, Heller S (June 2016). "Managing hypoglycaemia" (PDF). Best Practice & Research. Clinical Endocrinology & Metabolism. 30 (3): 413–30. doi:10.1016/j.beem.2016.06.004. PMID   27432075.
129. Dungan K, Merrill J, Long C, Binkley P (November 2019). "Effect of beta blocker use and type on hypoglycemia risk among hospitalized insulin requiring patients". Cardiovascular Diabetology. 18 (1): 163. doi: 10.1186/s12933-019-0967-1 . PMC   6882013 . PMID   31775749.
130. Shen WT, Lee J, Kebebew E, Clark OH, Duh QY (August 2006). "Selective use of steroid replacement after adrenalectomy: lessons from 331 consecutive cases". Archives of Surgery. 141 (8): 771–4, discussion 774–6. doi: 10.1001/archsurg.141.8.771 . PMID   16924084.
131. MacKenzie CR, Goodman SM (July 2016). "Stress Dose Steroids: Myths and Perioperative Medicine". Current Rheumatology Reports. 18 (7): 47. doi:10.1007/s11926-016-0595-7. PMID   27351679. S2CID   22000392.
132. Pazderska A, Pearce SH (June 2017). "Adrenal insufficiency — recognition and management". Clinical Medicine. 17 (3): 258–262. doi:10.7861/clinmedicine.17-3-258. PMC   6297573 . PMID   28572228.
133. Zelinka T, Musil Z, Dušková J, Burton D, Merino MJ, Milosevic D, et al. (October 2011). "Metastatic pheochromocytoma: does the size and age matter?". European Journal of Clinical Investigation. 41 (10): 1121–8. doi:10.1111/j.1365-2362.2011.02518.x. PMC   3170415 . PMID   21692797.
134. Hamidi O, Young WF, Gruber L, Smestad J, Yan Q, Ponce OJ, et al. (November 2017). "Outcomes of patients with metastatic phaeochromocytoma and paraganglioma: A systematic review and meta-analysis". Clinical Endocrinology. 87 (5): 440–450. doi:10.1111/cen.13434. PMC   5854189 . PMID   28746746.
135. "Metastatic catecholamine-secreting paraganglioma (extra-adrenal pheochromocytoma)". The American Journal of Medicine. 61 (4): 523–532. October 1976. doi:10.1016/0002-9343(76)90332-6. ISSN   0002-9343. PMID   973646.
136. Engstrand J, Strömberg C, Nilsson H, Freedman J, Jonas E (December 2019). "Synchronous and metachronous liver metastases in patients with colorectal cancer-towards a clinically relevant definition". World Journal of Surgical Oncology. 17 (1): 228. doi: 10.1186/s12957-019-1771-9 . PMC   6933908 . PMID   31878952.
137. Ferrer-Inaebnit E, Segura-Sampedro JJ, Alfonso-García M, González-Argente X, Morales-Soriano R (January 2021). "Cytoreductive surgery in functioning peritoneal pheochromocytomatosis". Cirugia Espanola. 99 (1): 73–76. doi:10.1016/j.ciresp.2020.03.010. PMID   32402418. S2CID   219405349.
138. Corssmit EP, Snel M, Kapiteijn E (January 2020). "Malignant pheochromocytoma and paraganglioma: management options". Current Opinion in Oncology. 32 (1): 20–26. doi:10.1097/cco.0000000000000589. PMID   31599769. S2CID   204029843.
139. Roman-Gonzalez A, Zhou S, Ayala-Ramirez M, Shen C, Waguespack SG, Habra MA, et al. (July 2018). "Impact of Surgical Resection of the Primary Tumor on Overall Survival in Patients With Metastatic Pheochromocytoma or Sympathetic Paraganglioma". Annals of Surgery. 268 (1): 172–8. doi:10.1097/sla.0000000000002195. PMID   28257320. S2CID   22915608.
140. Ellis RJ, Patel D, Prodanov T, Sadowski S, Nilubol N, Adams K, et al. (September 2013). "Response after surgical resection of metastatic pheochromocytoma and paraganglioma: can postoperative biochemical remission be predicted?". Journal of the American College of Surgeons. 217 (3): 489–96. doi:10.1016/j.jamcollsurg.2013.04.027. PMC   3770940 . PMID   23891076.
141. Jimenez C, Rohren E, Habra MA, Rich T, Jimenez P, Ayala-Ramirez M, Baudin E (August 2013). "Current and future treatments for malignant pheochromocytoma and sympathetic paraganglioma". Current Oncology Reports. 15 (4): 356–71. doi:10.1007/s11912-013-0320-x. PMID   23674235. S2CID   1167562.
142. Pappachan JM, Raskauskiene D, Sriraman R, Edavalath M, Hanna FW (July 2014). "Diagnosis and management of pheochromocytoma: a practical guide to clinicians". Current Hypertension Reports. 16 (7): 442. doi:10.1007/s11906-014-0442-z. PMID   24792093. S2CID   38357313.
143. Buhl T, Mortensen J, Kjaer A (March 2002). "I-123 MIBG imaging and intraoperative localization of metastatic pheochromocytoma: a case report". Clinical Nuclear Medicine. 27 (3): 183–5. doi:10.1097/00003072-200203000-00007. PMID   11852305. S2CID   11485950.
144. De Filpo G, Maggi M, Mannelli M, Canu L (June 2020). "Management and outcome of metastatic pheochromocytomas/paragangliomas: an overview". Journal of Endocrinological Investigation. 44 (1): 15–25. doi:10.1007/s40618-020-01344-z. PMID   32602077. S2CID   220150512.
145. Breen W, Bancos I, Young WF, Bible KC, Laack NN, Foote RL, Hallemeier CL (2017-11-22). "External beam radiation therapy for advanced/unresectable malignant paraganglioma and pheochromocytoma". Advances in Radiation Oncology. 3 (1): 25–29. doi:10.1016/j.adro.2017.11.002. PMC   5856976 . PMID   29556576.
146. Kohlenberg J, Welch B, Hamidi O, Callstrom M, Morris J, Sprung J, et al. (February 2019). "Efficacy and Safety of Ablative Therapy in the Treatment of Patients with Metastatic Pheochromocytoma and Paraganglioma". Cancers. 11 (2): 195. doi: 10.3390/cancers11020195 . PMC   6407137 . PMID   30736463.
147. Niemeijer ND, Alblas G, van Hulsteijn LT, Dekkers OM, Corssmit EP (November 2014). "Chemotherapy with cyclophosphamide, vincristine and dacarbazine for malignant paraganglioma and pheochromocytoma: systematic review and meta-analysis". Clinical Endocrinology. 81 (5): 642–51. doi: 10.1111/cen.12542 . PMID   25041164. S2CID   5407678.
148. Averbuch SD, Steakley CS, Young RC, Gelmann EP, Goldstein DS, Stull R, Keiser HR (August 1988). "Malignant pheochromocytoma: effective treatment with a combination of cyclophosphamide, vincristine, and dacarbazine". Annals of Internal Medicine. 109 (4): 267–73. doi:10.7326/0003-4819-109-4-267. PMID   3395037.
149. Huang H, Abraham J, Hung E, Averbuch S, Merino M, Steinberg SM, et al. (October 2008). "Treatment of malignant pheochromocytoma/paraganglioma with cyclophosphamide, vincristine, and dacarbazine: recommendation from a 22-year follow-up of 18 patients". Cancer. 113 (8): 2020–8. doi:10.1002/cncr.23812. PMC   9094399 . PMID   18780317. S2CID   205653109.
150. Nomura K, Kimura H, Shimizu S, Kodama H, Okamoto T, Obara T, Takano K (August 2009). "Survival of patients with metastatic malignant pheochromocytoma and efficacy of combined cyclophosphamide, vincristine, and dacarbazine chemotherapy". The Journal of Clinical Endocrinology and Metabolism. 94 (8): 2850–6. doi: 10.1210/jc.2008-2697 . PMID   19470630.
151. Jawed I, Velarde M, Därr R, Wolf KI, Adams K, Venkatesan AM, et al. (July 2018). "Continued Tumor Reduction of Metastatic Pheochromocytoma/Paraganglioma Harboring Succinate Dehydrogenase Subunit B Mutations with Cyclical Chemotherapy". Cellular and Molecular Neurobiology. 38 (5): 1099–1106. doi:10.1007/s10571-018-0579-4. PMC   5976545 . PMID   29623478.
152. Tena I, Gupta G, Tajahuerce M, Benavent M, Cifrián M, Falcon A, et al. (2018). "Successful Second-Line Metronomic Temozolomide in Metastatic Paraganglioma: Case Reports and Review of the Literature". Clinical Medicine Insights: Oncology. 12: 1179554918763367. doi:10.1177/1179554918763367. PMC   5922490 . PMID   29720885.
153. Tong A, Li M, Cui Y, Ma X, Wang H, Li Y (2020). "Temozolomide Is a Potential Therapeutic Tool for Patients With Metastatic Pheochromocytoma/Paraganglioma-Case Report and Review of the Literature". Frontiers in Endocrinology. 11: 61. doi: 10.3389/fendo.2020.00061 . PMC   7040234 . PMID   32132978.
154. Hadoux J, Favier J, Scoazec JY, Leboulleux S, Al Ghuzlan A, Caramella C, et al. (December 2014). "SDHB mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paraganglioma". International Journal of Cancer. 135 (11): 2711–20. doi: 10.1002/ijc.28913 . PMID   24752622. S2CID   23557293.
155. Pryma DA, Chin BB, Noto RB, Dillon JS, Perkins S, Solnes L, et al. (May 2019). "131I-MIBG Therapy in Patients with Advanced Pheochromocytoma or Paraganglioma". Journal of Nuclear Medicine. 60 (5): 623–630. doi:10.2967/jnumed.118.217463. PMC   6495236 . PMID   30291194.
156. Agrawal A, Rangarajan V, Shah S, Puranik A, Purandare N (November 2018). "MIBG (metaiodobenzylguanidine) theranostics in pediatric and adult malignancies". The British Journal of Radiology. 91 (1091): 20180103. doi:10.1259/bjr.20180103. PMC   6475939 . PMID   30048149.
157. Carrasquillo JA, Pandit-Taskar N, Chen CC (May 2016). "I-131 Metaiodobenzylguanidine Therapy of Pheochromocytoma and Paraganglioma". Seminars in Nuclear Medicine. 46 (3): 203–14. doi:10.1053/j.semnuclmed.2016.01.011. PMID   27067501.
158. Kong G, Grozinsky-Glasberg S, Hofman MS, Callahan J, Meirovitz A, Maimon O, et al. (September 2017). "Efficacy of Peptide Receptor Radionuclide Therapy for Functional Metastatic Paraganglioma and Pheochromocytoma". The Journal of Clinical Endocrinology and Metabolism. 102 (9): 3278–87. doi: 10.1210/jc.2017-00816 . PMID   28605448. S2CID   3759391.
159. Strosberg J, Wolin E, Chasen B, Kulke M, Bushnell D, Caplin M, et al. (September 2018). "177Lu-Dotatate in the Phase III NETTER-1 Trial". Journal of Clinical Oncology. 36 (25): 2578–84. doi:10.1200/JCO.2018.78.5865. PMC   6366953 . PMID   29878866.
160. Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, et al. (January 2017). "177Lu-Dotatate for Midgut Neuroendocrine Tumors". The New England Journal of Medicine. 376 (2): 125–135. doi:10.1056/NEJMoa1607427. PMC   5895095 . PMID   28076709.
161. Vyakaranam AR, Crona J, Norlén O, Granberg D, Garske-Román U, Sandström M, et al. (June 2019). "177Lu-DOTATATE". Cancers. 11 (7). doi: 10.3390/cancers11070909 . PMC   6678507 . PMID   31261748.
162. Satapathy S, Mittal BR, Bhansali A (December 2019). "Peptide receptor radionuclide therapy in the management of advanced pheochromocytoma and paraganglioma: A systematic review and meta-analysis". Clinical Endocrinology. 91 (6): 718–727. doi:10.1111/cen.14106. PMID   31569282. S2CID   203622655.
163. Wolf KI, Jha A, van Berkel A, Wild D, Janssen I, Millo CM, et al. (June 2019). "177Lu-DOTATATE". Nuclear Medicine and Molecular Imaging. 53 (3): 223–230. doi:10.1007/s13139-019-00579-w. PMC   6554376 . PMID   31231443.
164. "NCI Dictionary of Cancer Terms — National Cancer Institute". www.cancer.gov. 2011-02-02. Retrieved 2020-08-18.
165. "Pheochromocytoma — National Cancer Institute". www.cancer.gov. 2020-02-12. Retrieved 2020-08-18.
166. Noshiro T, Shimizu K, Watanabe T, Akama H, Shibukawa S, Miura W, et al. (January 2000). "Changes in clinical features and long-term prognosis in patients with pheochromocytoma". American Journal of Hypertension. 13 (1 Pt 1): 35–43. doi: 10.1016/S0895-7061(99)00139-9 . PMID   10678269.
167. Hescot S, Curras-Freixes M, Deutschbein T, van Berkel A, Vezzosi D, Amar L, et al. (June 2019). "Prognosis of Malignant Pheochromocytoma and Paraganglioma (MAPP-Prono Study): A European Network for the Study of Adrenal Tumors Retrospective Study". The Journal of Clinical Endocrinology and Metabolism. 104 (6): 2367–74. doi: 10.1210/jc.2018-01968 . PMID   30715419.
168. Hamidi O (June 2019). "Metastatic pheochromocytoma and paraganglioma: recent advances in prognosis and management". Current Opinion in Endocrinology, Diabetes and Obesity. 26 (3): 146–154. doi:10.1097/med.0000000000000476. PMID   30893083. S2CID   84844032.
169. Pacak K, Eisenhofer G, Ahlman H, Bornstein SR, Gimenez-Roqueplo AP, Grossman AB, et al. (February 2007). "Pheochromocytoma: recommendations for clinical practice from the First International Symposium. October 2005". Nature Clinical Practice. Endocrinology & Metabolism. 3 (2): 92–102. doi:10.1038/ncpendmet0396. PMID   17237836. S2CID   23952363.
170. Chen H, Sippel RS, O'Dorisio MS, Vinik AI, Lloyd RV, Pacak K (August 2010). "The North American Neuroendocrine Tumor Society consensus guideline for the diagnosis and management of neuroendocrine tumors: pheochromocytoma, paraganglioma, and medullary thyroid cancer". Pancreas. 39 (6): 775–83. doi:10.1097/MPA.0b013e3181ebb4f0. PMC   3419007 . PMID   20664475.
171. Sutton MG, Sheps SG, Lie JT (June 1981). "Prevalence of clinically unsuspected pheochromocytoma. Review of a 50-year autopsy series". Mayo Clinic Proceedings. 56 (6): 354–60. PMID   6453259.
172. Kim JH, Moon H, Noh J, Lee J, Kim SG (March 2020). "Epidemiology and Prognosis of Pheochromocytoma/Paraganglioma in Korea: A Nationwide Study Based on the National Health Insurance Service". Endocrinology and Metabolism. 35 (1): 157–164. doi:10.3803/EnM.2020.35.1.157. PMC   7090309 . PMID   32207276.
173. Berends AM, Buitenwerf E, de Krijger RR, Veeger NJ, van der Horst-Schrivers AN, Links TP, Kerstens MN (May 2018). "Incidence of pheochromocytoma and sympathetic paraganglioma in the Netherlands: A nationwide study and systematic review" (PDF). European Journal of Internal Medicine. 51: 68–73. doi:10.1016/j.ejim.2018.01.015. PMID   29361475. S2CID   207232057.
174. Ebbehoj AL, Sondergaard E, Trolle C, Stochholm K, Poulsen PL (2017-05-03). "The epidemiology of pheochromocytoma: increasing incidence and changing clinical presentation. A population-based retrospective study 1977–2015". Endocrine Abstracts. doi:10.1530/endoabs.49.oc1.4. ISSN   1479-6848.
175. Aygun N, Uludag M (2020-06-03). "Pheochromocytoma and Paraganglioma: From Epidemiology to Clinical Findings". Sisli Etfal Hastanesi Tip Bulteni. 54 (2): 159–168. doi:10.14744/SEMB.2020.18794. PMC   7326683 . PMID   32617052.
176. Antonio K, Valdez MM, Mercado-Asis L, Taïeb D, Pacak K (February 2020). "Pheochromocytoma/paraganglioma: recent updates in genetics, biochemistry, immunohistochemistry, metabolomics, imaging and therapeutic options". Gland Surgery. 9 (1): 105–123. doi: 10.21037/gs.2019.10.25 . PMC   7082276 . PMID   32206603.
177. Conzo G, Pasquali D, Colantuoni V, Circelli L, Tartaglia E, Gambardella C, et al. (2014-05-01). "Current concepts of pheochromocytoma". International Journal of Surgery. 12 (5): 469–74. doi: 10.1016/j.ijsu.2014.04.001 . PMID   24727002.
178. Sugrue C (1800). "A Case of Gastrodynia". Med Phys J. 4: 228–331.
179. Bausch B, Tischler AS, Schmid KW, Leijon H, Eng C, Neumann HP (July 2017). "Max Schottelius: Pioneer in Pheochromocytoma". Journal of the Endocrine Society. 1 (7): 957–964. doi:10.1210/js.2017-00208. PMC   5689150 . PMID   29264546.
180. Fränkel F (February 1886). "Ein Fall von doppelseitigem, völlig latent verlaufenen Nebennierentumor und gleichzeitiger Nephritis mit Veränderungen am Circulationsapparat und Retinitis". Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin. 103 (2): 244–263. doi:10.1007/bf01938677. ISSN   0945-6317. S2CID   31941439.
181. Kantorovich V, Pacak K (2010). "Pheochromocytoma and paraganglioma". Neuroendocrinology — Pathological Situations and Diseases. Progress in Brain Research. Vol. 182. Elsevier. pp. 343–73. doi:10.1016/s0079-6123(10)82015-1. ISBN   978-0-444-53616-7. PMC   4714594 . PMID   20541673.
182. Kiernan CM, Solórzano CC (January 2016). "Pheochromocytoma and Paraganglioma: Diagnosis, Genetics, and Treatment". Surgical Oncology Clinics of North America. 25 (1): 119–38. doi:10.1016/j.soc.2015.08.006. PMID   26610778.
183. Welbourn RB (July 1987). "Early surgical history of phaeochromocytoma". The British Journal of Surgery. 74 (7): 594–6. doi:10.1002/bjs.1800740717. PMID   3304519. S2CID   40507310.
184. Jacob M, Macwana S, Vivekanand D (March 2015). "Anaesthetic management of a case of adrenal and extra-adrenal phaeochromocytoma for preoperative embolisation". Indian Journal of Anaesthesia. 59 (3): 196–7. doi: 10.4103/0019-5049.153046 . PMC   4378085 . PMID   25838596.
185. Boening A, Burger H (January 2018). ""If You Hear Hoof Beats, Think Horses, Not Zebras"". The Thoracic and Cardiovascular Surgeon Reports. 7 (1): e35. doi:10.1055/s-0038-1660808. PMC   6033608 . PMID   29984129.
186. "Rare Disease Day 2021 – 28 Feb". Rare Disease Day – 28 Feb 2021. Retrieved 2020-08-26.
187. "Home". NORD (National Organization for Rare Disorders). Retrieved 2020-08-26.
188. Sanders L (2019-10-30). "Why Did the Young Mother Have Searing Head Pain and a Racing Heart?". The New York Times. ISSN   0362-4331 . Retrieved 2020-08-26.
189. "Neuroendocrine Cancer Survivor Featured on Discovery Fit & Health TV Show". Carcinoid Cancer Foundation. 2012-07-08. Retrieved 2020-08-26.
190. "VHL Family Alliance Applauds Grey's Anatomy for Featuring von Hippel-Lindau Disease". www.prnewswire.com (Press release). Retrieved 2020-08-26.
191. Kevin (2011-01-12). "Mischaracterizations by the popular media of medical conditions". KevinMD.com. Retrieved 2020-08-26.
192. "'Grey's Anatomy' Features Rare Disease on Three-Episode Series". ABC News. Retrieved 2020-08-26.

Further reading

• Pourian M, Mostafazadeh DB, Soltani A (2015). "Does this patient have pheochromocytoma? A systematic review of clinical signs and symptoms". Journal of Diabetes and Metabolic Disorders. 15: 11. doi: 10.1186/s40200-016-0230-1 . PMC   4815191 . PMID   27034920.
• Else T, Greenberg S, Fishbein L (September 2023). Hereditary Paraganglioma-Pheochromocytoma Syndromes. GeneReviews® [Internet]. University of Washington, Seattle. PMID   20301715. NBK1548.

External links

• "General Information About Pheochromocytoma and Paraganglioma" from the National Cancer Institute
• Pheochromocytoma and Paraganglioma from the American Society of Clinical Oncology
• Pheochromocytoma; Rare Disease Database from the National Organization for Rare Disorders
• What's to Know about Pheochromocytoma from Medical News Today
• MedlinePlus Overview pheochromocytoma